



**HAL**  
open science

## Weak neuronal glycolysis sustains cognition and organismal fitness

Daniel Jimenez-Blasco, Jesús Agulla, Rebeca Lapresa, Marina Garcia-Macia, Veronica Bobo-Jimenez, Dario Garcia-Rodriguez, Israel Manjarres-Raza, Emilio Fernandez, Yannick Jeanson, Spiro Khoury, et al.

► **To cite this version:**

Daniel Jimenez-Blasco, Jesús Agulla, Rebeca Lapresa, Marina Garcia-Macia, Veronica Bobo-Jimenez, et al.. Weak neuronal glycolysis sustains cognition and organismal fitness. *Nature Metabolism*, 2023, 6, pp.1253 - 1267. 10.1038/s42255-024-01049-0 . hal-04670586

**HAL Id: hal-04670586**

**<https://hal.science/hal-04670586>**

Submitted on 12 Aug 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

# Weak neuronal glycolysis sustains cognition and organismal fitness

Received: 7 July 2023

Accepted: 15 April 2024

Published online: 24 May 2024

 Check for updates

Daniel Jimenez-Blasco <sup>1,2,3</sup>, Jesús Agulla <sup>1,2</sup>, Rebeca Lapresa <sup>1,2</sup>,  
Marina Garcia-Macia <sup>1,2,3</sup>, Veronica Bobo-Jimenez<sup>1,2</sup>,  
Dario Garcia-Rodriguez <sup>1,2,3</sup>, Israel Manjarres-Raza <sup>1,2,3</sup>, Emilio Fernandez<sup>1,2,3</sup>,  
Yannick Jeanson <sup>4</sup>, Spiro Khoury <sup>4,5</sup>, Jean-Charles Portais<sup>4,5,6</sup>, Daniel Padro<sup>7</sup>,  
Pedro Ramos-Cabrer <sup>7,8</sup>, Peter Carmeliet <sup>9,10</sup>, Angeles Almeida <sup>1,2</sup> &  
Juan P. Bolaños <sup>1,2,3</sup> 

The energy cost of neuronal activity is mainly sustained by glucose<sup>1,2</sup>. However, in an apparent paradox, neurons modestly metabolize glucose through glycolysis<sup>3–6</sup>, a circumstance that can be accounted for by the constant degradation of 6-phosphofructo-2-kinase–fructose-2,6-bisphosphatase-3 (PFKFB3)<sup>3,7,8</sup>, a key glycolysis-promoting enzyme. To evaluate the *in vivo* physiological importance of this hypoglycolytic metabolism, here we genetically engineered mice with their neurons transformed into active glycolytic cells through *Pfkfb3* expression. *In vivo* molecular, biochemical and metabolic flux analyses of these neurons revealed an accumulation of anomalous mitochondria, complex I disassembly, bioenergetic deficiency and mitochondrial redox stress. Notably, glycolysis-mediated nicotinamide adenine dinucleotide (NAD<sup>+</sup>) reduction impaired sirtuin-dependent autophagy. Furthermore, these mice displayed cognitive decline and a metabolic syndrome that was mimicked by confining *Pfkfb3* expression to hypothalamic neurons. Neuron-specific genetic ablation of mitochondrial redox stress or brain NAD<sup>+</sup> restoration corrected these behavioural alterations. Thus, the weak glycolytic nature of neurons is required to sustain higher-order organismal functions.

The proteolytic destabilization of PFKFB3 in neurons takes place upon polyubiquitination by the E3 ubiquitin ligase APC/C (anaphase-promoting complex, also known as the cyclosome)<sup>3</sup>. APC/C can be activated by either of the cofactors CDH1 (cell division cycle 20 homolog 1) or CDC20 (cell division cycle 20)<sup>7</sup>. However, CDC20 is not present in differentiated neurons<sup>8</sup>; hence, CDH1 is the only cofactor responsible for the observed high APC/C activity that leads to PFKFB3 protein destabilization and neuronal hypoglycolysis<sup>3</sup>. Stabilization of endogenous neuronal PFKFB3 takes place in several disease conditions<sup>9,10</sup> and during development<sup>6</sup>. In addition, aberrant hyperglycolysis takes place in Alzheimer's disease neurons<sup>11</sup>. However, the *in vivo* physiological importance of weak adult neuronal glycolysis

remains unknown, a limitation that has led to controversies<sup>1</sup>, thus hindering a better knowledge of brain function in health and disease. To address this issue, we aimed to generate a genetic mouse model able to boost glycolysis in neurons by means of *Pfkfb3* expression during adulthood. First, conditional *Cdh1*-knockout (*Cdh1*<sup>lox/lox</sup>) mice<sup>12</sup> were mated with mice expressing Cre recombinase under the control of the neuron-specific *Camk2a* (also known as *CamkIIa*) promoter, which is widely expressed across the brain, mainly in the hippocampus, neocortex, striatum and amygdala as from the third postnatal week<sup>13</sup>. As expected, *CamkIIa-Cdh1*<sup>-/-</sup> progeny showed PFKFB3 protein stabilization in neurons of the adult brain (Extended Data Fig. 1a). However, cyclin B1 and Rho-associated coiled-coil-containing protein kinase 2

A full list of affiliations appears at the end of the paper. ✉ e-mail: [jbolanos@usal.es](mailto:jbolanos@usal.es)

(ROCK2), that is, two proteins known to be APC/C–CDH1 substrates that cause neurotoxicity<sup>8</sup> and cognitive decline<sup>14</sup>, were also found to be stabilized (Extended Data Fig. 1a). These data did not persuade us that inhibition of APC/C–CDH1 activity would be a suitable strategy to specifically assess the in vivo impact of active glycolysis in neurons. To overcome this issue, we next generated, by homologous recombination in the *Rosa26* locus, a transgenic mouse harbouring the full-length cDNA for *Pfkfb3* (Fig. 1a). A floxed (*loxP*-flanked) transcriptional stop cassette was incorporated between *Pfkfb3* cDNA and the CAG promoter (*Pfkfb3*<sup>lox/+</sup>) to eventually obtain tissue- and time-specific expression of *Pfkfb3* in vivo (Fig. 1a). To ascertain the efficacy of this strategy, *Pfkfb3*<sup>lox/+</sup> mice were mated with *CamkIIa-cre* mice to generate *CamkIIa-Pfkfb3* (Fig. 1a) mice. *Pfkfb3*<sup>lox/+</sup> littermates were used as controls (wild type; WT) (Fig. 1a). *CamkIIa-Pfkfb3* mouse brains showed enhanced PFKFB3 protein levels, as judged by western blotting of all areas analysed such as the cortex, hippocampus and hypothalamus (Fig. 1b and Extended Data Fig. 1b) as well as by hippocampal immunocytochemistry (Extended Data Fig. 1c).


In contrast to neurons, APC/C–CDH1 activity is low in astrocytes and accounts for their naturally higher PFKFB3 abundance and glycolytic phenotype<sup>3</sup>. To ascertain whether the increase in PFKFB3 protein in the brain of *CamkIIa-Pfkfb3* mice is neuron specific, neurons and astrocytes were immunomagnetically purified, and PFKFB3 protein levels were analysed in both cell types by western blotting. As shown in Fig. 1c (Extended Data Fig. 1d), the abundance of PFKFB3 protein in *CamkIIa-Pfkfb3* neurons is similar to that found in wild-type astrocytes. This indicates that the abundance of PFKFB3 protein in neurons of the *CamkIIa-Pfkfb3* mouse model is moderately high enough to reach levels comparable with those physiologically found in neighbouring astrocytes. Moreover, sustained *Pfkfb3* expression does not result in overwhelming of APC/C–CDH1 ubiquitin ligase or proteasomal activities, as the protein levels of ROCK2 and cyclin B1 (APC/C–CDH1 substrates<sup>8,14</sup>) do not increase in neurons isolated from *CamkIIa-Pfkfb3* mice (Fig. 1c and Extended Data Fig. 1d). To assess whether PFKFB3 protein stabilization in *CamkIIa-Pfkfb3* neurons is functional, we used two strategies. First, in vivo <sup>1</sup>H magnetic resonance spectroscopy (<sup>1</sup>H MRS) analysis was performed in the *CamkIIa-Pfkfb3* mouse brain (Extended Data Fig. 1e), which revealed an enhancement in the concentration of lactate (Fig. 1d), suggesting increased glycolysis. Second, *CamkIIa-Pfkfb3* mice were intraperitoneally injected with [<sup>13</sup>C]glucose, and <sup>13</sup>C-labelled glycolytic intermediates were assessed in brain extracts by mass spectrometry (MS). As shown in Fig. 1e (Extended Data Fig. 1f,g), the ratio of fructose 1,6-bisphosphate (F16BP) versus fructose 6-phosphate (F6P) (F16BP/F6P), that is, the product and substrate of 6-phosphofructo-1-kinase (PFK1), respectively, was increased, indicating PFK1 activation in the brain of the *CamkIIa-Pfkfb3* mice. Moreover, <sup>13</sup>C mass spectrometry analysis also revealed that levels of the downstream glycolytic intermediaries phosphoenolpyruvate, pyruvate and lactate were also enhanced in *CamkIIa-Pfkfb3* mice (Fig. 1e), indicating an efficient, otherwise moderate increase in neuronal PFKFB3 protein levels that leads to PFK1 activation and enhanced glycolytic flux in vivo.

To validate glycolytic flux activation in neurons, these cells were cultured from *Pfkfb3*<sup>lox/+</sup> mouse embryos and, once differentiated, transduced with adenovirus expressing Cre recombinase under the cytomegalovirus (CMV) promoter (adeno-associated virus (AAV)-CMV-Cre-GFP) to generate *Pfkfb3*-expressing (*Pfkfb3*) neurons. *Pfkfb3*<sup>lox/+</sup> neurons transduced with the AAV lacking Cre recombinase (AAV-CMV-GFP) were used as controls (wild type) (Fig. 1f). As shown in Extended Data Fig. 1h, levels of PFKFB3 protein increased, and its functional activity was confirmed as judged by enhancement in the PFKFB3 product fructose 2,6-bisphosphate (F26BP) in *Pfkfb3* neurons (Fig. 1g). These cells had higher glycolytic flux, as analysed by the rate of [<sup>3</sup>H]glucose incorporation into <sup>3</sup>H<sub>2</sub>O, a bona fide index of glycolysis<sup>3</sup> (Fig. 1h). As glycolysis and the pentose phosphate pathway (PPP) are inversely correlated in neurons<sup>15</sup>, we determined the PPP flux in

*Pfkfb3* neurons by estimating the difference in <sup>14</sup>CO<sub>2</sub> production from [<sup>1-14</sup>C]glucose (decarboxylated during the PPP and the tricarboxylic acid (TCA) cycle) and [<sup>6-14</sup>C]glucose (decarboxylated during the TCA cycle<sup>16,17</sup>). As shown in Fig. 1i (Extended Data Fig. 1i), PPP flux decreased in *Pfkfb3* neurons. By producing nicotinamide adenine dinucleotide phosphate (NADPH(H<sup>+</sup>)), the PPP sustains the regeneration of reduced glutathione (GSH) from its oxidized form (GSSG)<sup>17</sup>. Accordingly, GSH (reduced and total forms) levels decreased and GSSG levels increased in *Pfkfb3* neurons, resulting in enhanced glutathione oxidation (increased GSSG/GSH ratio) (Fig. 1j and Extended Data Fig. 1j). These results were confirmed in vivo by brain [<sup>1</sup>H]MRS analysis in *CamkIIa-Pfkfb3* mice, as judged by the decreased GSH signal (Fig. 1k), despite the weaker magnitude that reflects mixed cell types. These data agree with previous observations indicating that the PPP is an advantageous metabolic pathway for neurons<sup>17–19</sup>.

Given that GSH is an antioxidant, we next searched for possible redox stress in *Pfkfb3* neurons. Reactive oxygen species (ROS) were thus assessed using two approaches. Using Amplex Red, we observed an increase in fluorescence that was potentiated by rotenone (Fig. 2a), suggesting enhanced ROS by forward electron transfer at mitochondrial complex I (CI). We next used the mitochondrial-specific probe MitoSOX, which revealed increased mitochondrial ROS (Fig. 2b). To further confirm the mitochondrial origin of these ROS, we used a genetic approach to express mitochondrial matrix-tagged catalase (*mCat*<sup>lox/+</sup>)<sup>20</sup>. Mating *Pfkfb3*<sup>lox/+</sup> mice with *mCat*<sup>lox/+</sup> mice generated double-transgenic *Pfkfb3*<sup>lox/+</sup>; *mCat*<sup>lox/+</sup> mice and siblings harbouring either genotype alone, namely, *Pfkfb3*<sup>lox/+</sup> or *mCat*<sup>lox/+</sup> (Extended Data Fig. 2a). Littermate embryos were individually genotyped and used to obtain neurons in primary culture (Extended Data Fig. 2b). Transduction of *Pfkfb3*<sup>lox/+</sup>; *mCat*<sup>lox/+</sup> and *Pfkfb3*<sup>lox/+</sup>; *mCat*<sup>lox/+</sup> cells with AAV-CMV-Cre-GFP yielded *Pfkfb3*, *mCat* or *Pfkfb3-mCat* neurons, respectively (Extended Data Fig. 2b); controls were *Pfkfb3*<sup>lox/+</sup> cells transduced with AAV-CMV-GFP (Extended Data Fig. 2b). The increases in rotenone-induced Amplex Red and MitoSOX fluorescence signal observed in *Pfkfb3* neurons were abolished in *Pfkfb3-mCat* neurons (Fig. 2a,b), confirming the mitochondrial matrix origin of the ROS signal (mROS). To corroborate these findings in vivo, *CamkIIa-Pfkfb3* mice were intravenously transduced with adenovirus expressing green fluorescent protein (GFP) under the control of the neuron-specific promoter hSyn (AAV-PHP.eb-hSyn-GFP) (Fig. 2c). The hippocampus and the hypothalamus were then dissociated, and GFP<sup>+</sup> cells were analysed by flow cytometry for MitoSOX fluorescence, the intensity of which was enhanced in both brain areas (Fig. 2d). To abolish mROS in neurons in vivo, double-transgenic *Pfkfb3*<sup>lox/+</sup>; *mCat*<sup>lox/+</sup> mice were mated with *CamkIIa-cre* mice to generate *CamkIIa-Pfkfb3-mCat* mice (Extended Data Fig. 2a). *Pfkfb3*<sup>lox/+</sup> (wild type) and *CamkIIa-mCat* mice were used as controls for *CamkIIa-Pfkfb3* and *CamkIIa-Pfkfb3-mCat* mice, respectively (Extended Data Fig. 2a). As depicted in Fig. 2d, the increased mROS of neurons from *CamkIIa-Pfkfb3* mice was not observed in *CamkIIa-Pfkfb3-mCat* mice. These data indicate that glycolytically active neurons experience mitochondrial redox stress in vivo.

As excess mROS may cause mitochondrial damage<sup>21</sup>, we next assessed the mitochondrial respiratory chain in *Pfkfb3* neurons. As shown in Fig. 2e, mitochondrial CI activity was impaired in *Pfkfb3* neurons but not in *Pfkfb3-mCat* neurons; however, complex II–III was unaffected (Fig. 2f). To further explore this, we determined the mitochondrial respiratory chain (MCR) assembly of mitochondrial proteins by blue native gel electrophoresis (BNGE). *Pfkfb3* neurons showed a selective loss of free CI according to the in-gel activity assay (Fig. 2g and Extended Data Fig. 2c). CI-specific activity analysis in *Pfkfb3* neurons revealed an increase in the deactive<sup>22</sup> form of the complex, which was not observed in *Pfkfb3-mCat* cells (Fig. 2h), indicating that mROS mediates CI deactivation and inhibition. Notably, free CI, that is, the fraction of CI that is not superassembled in supercomplexes, lost its NADH-binding module; however, this module was intact in



**Fig. 1 | In vivo neuron-specific *Pfkfb3* expression activates glycolysis and inhibits the PPP, causing redox stress.** **a**, Strategy used to generate neuron-specific *Pfkfb3*-expressing (*CamkIIα-Pfkfb3*) mice. p, promoter. **b**, Western blot for PFKFB3 protein in different areas of the *CamkIIα-Pfkfb3* mouse brain. β-Actin was used as a loading control (Extended Data Fig. 1b). MW, molecular weight; WT, wild type. **c**, Western blot for PFKFB3 protein in neurons and non-neuronal cells immunomagnetically isolated from *CamkIIα-Pfkfb3* mice. GFAP and TUJ1 were used as astrocyte- or neuron-enrichment and loading controls (Extended Data Fig. 1d). **d**, In vivo [<sup>1</sup>H]MRS analysis of the lactate/(pCr+Cr, phosphocreatine+creatine) ratio in the brain of *CamkIIα-Pfkfb3* mice. Data are mean ± s.e.m. P value is indicated (*n* = 5 mice per genotype; unpaired Student's *t*-test, two sided) (Extended Data Fig. 1e). AU, arbitrary units. **e**, In vivo <sup>13</sup>C-enrichment MS analysis of the F16BP/F6P ratio and the indicated glycolytic intermediates in the brain of *CamkIIα-Pfkfb3* mice. Data are mean ± s.e.m.


P value is indicated (*n* = 4 mice per genotype; unpaired Student's *t*-test, two sided) (Extended Data Fig. 1f). **f**, Adenoviral transduction strategy used to express *Pfkfb3* in brain cortical neurons in primary culture from *Pfkfb3*<sup>lox/+</sup> mice. Created with <https://www.biorender.com>. E, embryonic day. **g–j**, F26BP concentration (**g**), glycolytic flux as measured by the rate of [3-<sup>3</sup>H]glucose conversion into <sup>3</sup>H<sub>2</sub>O (**h**), PPP flux as measured by the difference in <sup>14</sup>CO<sub>2</sub> production from [1-<sup>14</sup>C]glucose and [6-<sup>14</sup>C]glucose (**i**) and glutathione redox status as measured by the ratio of GSSG versus GSH (**j**) in primary neurons. Data are mean ± s.e.m. P value is indicated; *n* = 3 (**g**), *n* = 12 (**h**, WT), *n* = 14 (**h**, *Pfkfb3*), *n* = 6 (**i**, WT), *n* = 8 (**i**, *Pfkfb3*), *n* = 9 (**j**, WT) and *n* = 12 (**j**, *Pfkfb3*) biologically independent cell culture preparations; unpaired Student's *t*-test, two sided (Extended Data Fig. 1h, i). **k**, In vivo [<sup>1</sup>H]MRS analysis of the GSH/(pCr+Cr) ratio in the brain of *CamkIIα-Pfkfb3* mice. Data are mean ± s.e.m. P value is indicated; *n* = 5 (WT) and *n* = 6 (*CamkIIα-Pfkfb3*) mice; unpaired Student's *t*-test, two sided.

supercomplex-assembled CI, and the ubiquinone-binding CI module was intact (Fig. 2g and Extended Data Fig. 2c). As these data suggest mitochondrial respiratory chain dysfunction, we next performed bioenergetic profile analysis using Seahorse technology. This revealed an impairment in basal, maximal and ATP-linked oxygen-consumption rates (OCRs) in *Pfkfb3* neurons that was corrected in *Pfkfb3-mCat* cells (Fig. 2i). Flow cytometry (Fig. 2j) and confocal microscopy (Extended Data Fig. 2d) analyses showed loss in the inner mitochondrial membrane potential ( $\Delta\psi_m$ ) in *Pfkfb3* neurons, an effect that was cancelled by mCat. Metabolomics analysis in the brain of the *CamkIIα-Pfkfb3* mice revealed significant alterations in metabolic pathways, including a reduced concentration of the TCA cycle intermediate citrate (Extended Data Fig. 2e). To confirm bioenergetic failure of neurons in vivo, hippocampal and MBH GFP<sup>+</sup> cells (Fig. 2c) were analysed by flow cytometry, which showed  $\Delta\psi_m$  loss in *CamkIIα-Pfkfb3* mice that was corrected in

*CamkIIα-Pfkfb3-mCat* mice (Extended Data Fig. 2f). These data indicate that neurons with active glycolysis undergo mROS-mediated deactivation of mitochondrial CI, causing bioenergetic failure.

Cytosolic NAD<sup>+</sup> regeneration is required for glycolysis<sup>23,24</sup>. However, dysfunctional mitochondria, such as those in *Pfkfb3* neurons, have impaired their ability to regenerate NAD<sup>+</sup><sup>24,25</sup>. The rates of glucose consumption and lactate production increased by ~2.5-fold and 1.3-fold, respectively (Extended Data Fig. 3a), showing that pyruvate-to-lactate conversion, while discretely increased by *Pfkfb3* expression (Fig. 1d, in vivo), does not wholly account for the high increase in the rate of glucose consumption. This is in good agreement with the occurrence in neurons of lactate dehydrogenase isoform 1 (LDH1)<sup>4,26</sup>, with a low pyruvate-to-lactate conversion rate and, therefore, a weak capacity to regenerate NAD<sup>+</sup>. We then sought to ascertain whether glucose would be transformed into lipids, a process that requires the conversion






**Fig. 2 | Neuron-specific *Pfkfb3* expression impairs mitochondrial bioenergetics via enhanced mitochondrial ROS.** **a**,  $H_2O_2$  production. Data are mean  $\pm$  s.e.m. *P* values are indicated; *n* = 5 biologically independent cell culture preparations; two-way ANOVA followed by Tukey's test. NS, not significant. **b**, Mitochondrial ROS production. Data are mean  $\pm$  s.e.m. *P* values are indicated; *n* = 10 (WT, *Pfkfb3*) or *n* = 9 (*mCat*, *Pfkfb3-mCat*) biologically independent cell culture preparations; one-way ANOVA followed by Tukey's test. **c**, In vivo AAV intravenous transduction strategy to express GFP in the neurons of *Pfkfb3<sup>lox/+</sup>* or *Camk1la-Pfkfb3* mice. HP, hippocampus. Created with <https://www.biorender.com> (Extended Data Fig. 2f). **d**, Mitochondrial ROS production in neurons isolated from mice transduced with AAV expressing GFP under the neuron-specific hSyn promoter. Data are mean  $\pm$  s.e.m. *P* values are indicated; *n* = 5 (WT) or *n* = 4 (*Camk1la-Pfkfb3*, *Camk1la-mCat*, *Camk1la-Pfkfb3-mCat*) mice; one-way ANOVA followed by Bonferroni correction (Extended Data Fig. 2f). **e**, Mitochondrial CI activity. Data are mean  $\pm$  s.e.m. *P* values are indicated; *n* = 6 (WT), *n* = 8 (*Pfkfb3*), *n* = 3 (*mCat*) or *n* = 9 (*Pfkfb3-mCat*) biologically independent cell culture preparations; one-way ANOVA followed by Bonferroni

correction. **f**, Mitochondrial complex II–III activity. Data are mean  $\pm$  s.e.m. *n* = 6 (WT, *Pfkfb3*), *n* = 3 (*mCat*) or *n* = 7 (*Pfkfb3-mCat*) biologically independent cell culture preparations; one-way ANOVA followed by Bonferroni correction. **g**, In-gel activity of CI (IGA-CI) and BNGE followed by immunoblotting for CI subunits NDUFS1 and NDUFA9, complex (C)III subunit UQCRC2, complex IV subunit MTCO1, complex V subunit ATP6 or complex II subunit SDHA in primary neurons (Extended Data Fig. 2c). **h**, Deactive mitochondrial CI activity. Data are mean  $\pm$  s.e.m. *P* values are indicated; *n* = 6 (WT, *Pfkfb3*) or *n* = 4 (*mCat*, *Pfkfb3-mCat*) biologically independent cell culture preparations; one-way ANOVA followed by Bonferroni correction. **i**, OCR analysis and calculated parameters. Data are mean  $\pm$  s.e.m. *P* values are indicated; *n* = 4 (WT, *Pfkfb3*) or *n* = 3 (*mCat*, *Pfkfb3-mCat*) biologically independent cell culture preparations; one-way ANOVA followed by Bonferroni correction. Ant, antimycin; olig, oligomycin; rot, rotenone. **j**, Mitochondrial membrane potential ( $\Delta\psi_m$ ). Data are mean  $\pm$  s.e.m. *P* values are indicated; *n* = 5 (WT), *n* = 8 (*Pfkfb3*), *n* = 3 (*mCat*) or *n* = 5 (*Pfkfb3-mCat*) biologically independent cell culture preparations; one-way ANOVA followed by Bonferroni correction (Extended Data Fig. 2d,f).

of pyruvate into citrate, which leaves mitochondria for lipid synthesis<sup>27,28</sup>. [ $^{14}C$ ]glucose conversion into [ $^{14}C$ ]lipids in *Pfkfb3* neurons increased (Fig. 3a) at the same rate as glycolysis (Fig. 1h), suggesting that the vast majority of glycolytically consumed glucose is destined for lipids. Interestingly, metabolomics analysis in the brain of these mice revealed data compatible with reduced lipolysis (Extended Data Fig. 2e), and in vivo  $^1H$ -MRS brain analysis of *Camk1la-Pfkfb3* mice showed increased lipid 13a and lipid 13b signals (Extended Data Fig. 3b), which denotes enhanced abundance of lipid droplets<sup>29,30</sup>. To confirm this, we assessed by western blotting the levels of perilipin 2 (PLIN2),

a lipid droplet-coating protein that limits the access of lipases, favouring the accumulation of lipids<sup>31</sup>. In cultured primary *Pfkfb3* neurons, PLIN2 levels were considerably increased (Extended Data Fig. 3c). Interestingly, in *Camk1la-Pfkfb3* mice in vivo, PLIN2 only modestly increased in the neuronal fraction (Extended Data Fig. 3d), but it accumulated abundantly in the non-neuronal fraction, which mostly includes glial cells (Extended Data Fig. 3d). These data strongly suggest that *Camk1la-Pfkfb3* neurons undergo enhanced synthesis of lipids, which may be partially or transiently stored as lipid droplets and destined for reserve or fuel of neighbouring glial cells. Because lipogenesis from



**Fig. 3 | Neuron-specific *Pfkfb3* expression inhibits sirtuin-mediated autophagy, causing motor and cognitive impairment via mitochondrial ROS.**

**a–d**, Lipogenesis rate (**a**), NAD<sup>+</sup> concentration (**b**), total HDAC activity (**c**) and sirtuin activity (**d**) in primary neurons. Data are mean ± s.e.m. *P* values are indicated; *n* = 6 (**a**, WT), *n* = 8 (**a**, *Pfkfb3*) or *n* = 3 (**b–d**) biologically independent cell culture preparations; unpaired Student's *t*-test, two sided (**a**, **c**); two-way ANOVA followed by Tukey's test (**b**, **d**). **e**, Immunoprecipitation (IP) of ATG7, followed by western blot for acetyl-lysine (Ac-Lys), ATG7 and sirtuin 1 (SIRT1) in primary neurons; *n* = 3 biologically independent cell culture preparations are shown (Extended Data Fig. 3f). **f**, Autophagic and mitophagic flux analyses by western blot for microtubule-associated proteins 1A/1B light chain 3B (LC3-I and LC3-II) in primary neurons incubated, or not, with NMN or lysosomal inhibitors (lys. inh.). β-Actin, loading control (Extended Data Fig. 3d). Exp, exposure. **g**, Autophagic flux analysis by western blot for LC3-I, LC3-II, p62, beclin 1, mitochondrial import receptor subunit TOM20 homolog (TOMM20) and voltage-dependent anion-selective channel protein (VDAC) in freshly obtained cortical and hippocampal slices from wild-

type (WT) or *Camk1la-Pfkfb3* mice, incubated, or not, with lysosomal inhibitors. β-Actin, loading control (Extended Data Fig. 3e). **h**, In vivo adeno-associated viral intravenous transduction strategy to express GFP or Cre recombinase in neurons of *Pfkfb3*<sup>lox/+</sup> mice to generate WT (AAV) and *Camk1la-Pfkfb3* (AAV) mice, respectively. Created with <https://www.biorender.com> (Extended Data Fig. 3i). i.p., intraperitoneal. **i**, Autophagic and mitophagic flux analyses by western blot for LC3-I, LC3-II, p62, TOMM20 and VDAC in freshly obtained hippocampal slices from WT (AAV) or *Camk1la-Pfkfb3* (AAV) mice, incubated, or not, with lysosomal inhibitors. β-Actin, loading control (Extended Data Fig. 3k). **j**, Novel object-recognition test in mice of the indicated genotypes. Data are mean ± s.e.m. *P* values are indicated; *n* = 12 (WT), *n* = 9 (*Camk1la-Pfkfb3*) or *n* = 7 (*Camk1la-mCat*, *Camk1la-Pfkfb3-mCat*) mice; one-way ANOVA followed by Bonferroni correction (**h–j**) or two-way ANOVA followed by Tukey's test (**k**). **k**, Novel object-recognition test in mice of the indicated genotypes. Data are mean ± s.e.m. *P* values are indicated; *n* = 4 (WT AAV), *n* = 7 (WT AAV with NMN), *n* = 5 (*Camk1la-Pfkfb3* AAV) or *n* = 6 (*Camk1la-Pfkfb3* AAV with NMN) mice; two-way ANOVA followed by Tukey's test.

glucose is not an NAD<sup>+</sup>-regenerating process, we assessed NAD<sup>+</sup> levels in neurons. As shown in Fig. 3b, NAD<sup>+</sup> concentrations were decreased in *Pfkfb3* neurons, suggesting that active glycolysis causes net NAD<sup>+</sup> consumption. This was confirmed by incubating *Pfkfb3* neurons with

the NAD<sup>+</sup> precursor nicotinamide mononucleotide (NMN), which fully restored NAD<sup>+</sup> levels (Fig. 3b). This NAD<sup>+</sup> loss could not be ascribed to intrinsic impairments in the activities of the NAD<sup>+</sup>-regenerating systems, namely the malate–aspartate and glycerol-3-phosphate shuttles,

which remained unchanged according to in vivo analyses (Extended Data Fig. 3e). NAD<sup>+</sup> is an essential substrate for sirtuin deacetylase activity<sup>32</sup>, which therefore should be affected by NAD<sup>+</sup> loss. Although histone deacetylase (HDAC) activity (reflecting total sirtuin activity) was unaltered (Fig. 3c), sirtuin-specific activity was impaired in *Pfkfb3* neurons, an effect that was rescued by NMN (Fig. 3d). Interestingly, ATG7, a protein that requires sirtuin-mediated deacetylation to promote autophagy<sup>32</sup>, was hyperacetylated (Fig. 3e and Extended Data Fig. 3f), suggesting impaired autophagy in glycolytically active neurons. To test this, we determined the autophagic flux, which was decreased in *Pfkfb3* neurons, an effect that was rescued by NMN (Fig. 3f and Extended Data Fig. 3g). This result was confirmed ex vivo in the cortex and hippocampus freshly dissected from the *CamkIIα-Pfkfb3* brain, where both the rates of autophagy and mitophagy were reduced (Fig. 3g and Extended Data Fig. 3h). To further ascertain whether NAD<sup>+</sup> restoration corrects these biochemical alterations in vivo, newly weaned *Pfkfb3<sup>lox/+</sup>* mice were intravenously transduced with adenovirus expressing Cre under the control of the *CamkIIα* promoter (AAV-PHP.eb-CamkIIα-Cre) (Fig. 3h), which efficiently expresses *Pfkfb3* in the cortex, hippocampus and hypothalamus (Extended Data Fig. 3i). One week after, NMN was intraperitoneally administered (100 mg per kg body weight) to these mice at three injections per week for 1 month. As shown in Extended Data Fig. 3j, this in vivo NMN treatment restored the decreased hippocampal NAD<sup>+</sup> levels observed in mice expressing neuronal *Pfkfb3* and rescued impaired autophagy and mitophagy (Fig. 3i and Extended Data Fig. 3k). These data indicate that glycolytically active neurons show an impaired autophagic flux and that, by modulating the NAD<sup>+</sup> pool, glycolysis regulates autophagy.


Next, we aimed to investigate whether the metabolic alterations occurring in glycolytically active neurons impacted their function and viability. According to the brain [<sup>1</sup>H]MRS analysis (Extended Data Fig. 4a), the neuronal functional markers *N*-acetylaspartate and its glutamyl derivative *N*-acetylaspartylglutamate were decreased in *CamkIIα-Pfkfb3* mice, which also showed astrogliosis as determined by glial fibrillary acidic protein (GFAP) staining (Extended Data Fig. 4b). Moreover, flow cytometry analysis of freshly isolated neurons from the hippocampus and hypothalamus of *CamkIIα-Pfkfb3* mice previously transduced with AAV-PHP.eb-hSyn-GFP revealed increased apoptotic neurons (Extended Data Fig. 4c). Moreover, immunocytochemical analysis of the *CamkIIα-Pfkfb3* hippocampus showed disruption of neuronal integrity, as demonstrated by βIII-tubulin (TUJ1) staining (Extended Data Fig. 4d). Notably, these alterations were corrected in *CamkIIα-Pfkfb3-mCat* mice (Extended Data Fig. 4c,d). These set of in vivo data confirm that glycolytic neurons undergo mitochondrial redox stress that contributes to neuronal dysfunction and damage. To address whether the metabolic and functional alterations that take place in glycolytically active neurons impact on the organismal level, we performed a range of behavioural tests. The open-field test (Extended Data Fig. 4e) revealed fear and/or anxiety in *CamkIIα-Pfkfb3* mice. These mice performed worse at the rotarod (Extended Data Fig. 4f) and treadmill (Extended Data Fig. 4g), indicating loss of motor activity, poor endurance and slowness. Furthermore, the novel object-recognition test showed short-term cognitive impairment (Fig. 3j). Female mice showed an identical phenotype (Extended Data Fig. 4h–k). Notably, these alterations were abolished in *CamkIIα-Pfkfb3-mCat* male mice (Fig. 3j and Extended Data Fig. 4e–g). Interestingly, behavioural alterations including motor discoordination, fear and/or anxiety and cognitive impairment were corrected by restoring brain NAD<sup>+</sup> levels in NMN-treated *Pfkfb3*-expressing mice (Fig. 3k and Extended Data Fig. 5a,b). Thus, the transformation of neurons into glycolytically active cells develops functional alterations in neurons and loss of cognitive performance.

To further characterize mice with glycolytically active neurons, we monitored weight. *CamkIIα-Pfkfb3* mice showed no weight change at 2.5 months, but body weight increased at the age of 8 months (Extended Data Fig. 6a). To boost this phenotype, mice were fed a

high-fat diet (HFD) from weaning for 21 weeks. As shown in Fig. 4a and Extended Data Fig. 6b, the weight of *CamkIIα-Pfkfb3* mice progressively increased, along with food intake (Fig. 4b), effects that were abolished in *CamkIIα-Pfkfb3-mCat* mice. In the neuronal ceroid lipofuscinosis *Cln7<sup>Δex2</sup>* mouse model, we previously observed neuronal PFKFB3 protein stabilization<sup>10</sup>. Here, we show that chronic (2.5 months, daily) intracerebroventricular administration of the PFKFB3-specific inhibitor AZ67 (ref. 33) in *Cln7<sup>Δex2</sup>* mice prevented the increase in weight gain observed in vehicle-treated *Cln7<sup>Δex2</sup>* mice (Extended Data Fig. 6c). Subcutaneous and abdominal white fat and brown fat (Extended Data Fig. 6d) were increased in *CamkIIα-Pfkfb3* mice but not in *CamkIIα-Pfkfb3-mCat* animals. Likewise, these mice revealed hepatomegaly and sarcopenia (Extended Data Fig. 6e). Levels of plasma triglycerides (Fig. 4c), free fatty acids (Fig. 4d), leptin (Fig. 4e) and insulin (Fig. 4f) were increased in *CamkIIα-Pfkfb3* mice and abolished in *CamkIIα-Pfkfb3-mCat* mice. Finally, *CamkIIα-Pfkfb3* mice were unable to reduce plasma glucose levels in the glucose overload-tolerance test (Fig. 4g and Extended Data Fig. 6f), whereas *CamkIIα-Pfkfb3-mCat* mice performed correctly in this test. Given that these observations suggest metabolic-like syndrome, we assessed the autophagy capacity of the mediobasal hypothalamus (MBH), as this process has been previously reported to be specifically impaired in the MBH<sup>34</sup>. Analysis of the MBH freshly dissected from *CamkIIα-Pfkfb3* mice revealed impaired autophagic flux (Fig. 4h and Extended Data Fig. 6g), an effect that was ablated in *CamkIIα-Pfkfb3-mCat* mice. To assess whether the anatomical origin of this phenotype is the MBH or whether it is the indirect consequence of impaired neuronal circuitry from other brain areas, we confined *Pfkfb3* expression to MBH neurons. Thus, *Pfkfb3<sup>lox/+</sup>* mice were stereotaxically injected with adenovirus harbouring Cre recombinase governed by the *CamkIIα* promoter (AAV-CamkIIα-Cre-GFP) in the arcuate nucleus of the MBH to induce *Pfkfb3* expression in the neurons of this brain area (MBH-nPfkfb3) (Fig. 4i). At the age of 21 weeks, no alterations in behavioural tests such as the open-field test (Extended Data Fig. 6h) and the novel object-recognition test (Fig. 4j) were observed, indicating lack of fear and anxiety, motor discoordination or cognitive disturbances. However, weight (Fig. 4k and Extended Data Fig. 6i) and food intake (Fig. 4l) increased in MBH-nPfkfb3 mice when compared with mice injected with AAV lacking Cre recombinase (AAV-CamkIIα-GFP). Moreover, these effects were accompanied by increased weight in white and brown (Extended Data Fig. 6j) adipose tissue, hepatomegaly (Extended Data Fig. 6k) and glucose intolerance (Fig. 4m and Extended Data Fig. 6l). Altogether, these results suggest that glycolytically active neurons of the arcuate nucleus impair hypothalamic control of food intake and organismal metabolism. The connection between metabolic-like syndrome and cognitive impairment upon aberrant neuronal glycolysis described here may open new therapeutic perspectives (Fig. 4n).

In conclusion, here we show that neurons actively preserve a persistent hypoglycolytic metabolism to boost the PPP, therefore avoiding redox stress-mediated mitochondrial impairment. Given the inefficiency of LDH1 (refs. 4,26), functional mitochondria are essential to regenerate cytosolic NAD<sup>+</sup> (ref. 35) via the malate and glycerol phosphate shuttles<sup>36</sup>, the activities of which remain intrinsically unaltered when transformed in glycolytically active cells. However, in these neurons, mitochondrial function is impaired, thus hindering their ability to regenerate NAD<sup>+</sup> regardless of shuttle activities, leading to autophagy impairment and cognitive deficiency (Fig. 4n). This mechanism could explain the pathogenic consequences of neuronal PFKFB3 stabilization<sup>9,10</sup> and the aberrant hyperglycolysis<sup>11</sup> taking place in Alzheimer's disease and other disease conditions. Moreover, we show that a similar pattern of events operates in *Pfkfb3*-expressing neurons of the MBH and triggers metabolic-like syndrome (Fig. 4n). Naturally, neuronal glycolysis is amenable to transient activation during glutamatergic neurotransmission<sup>25,37,38</sup> or hypoxia<sup>39</sup>, where this pathway has energetic functions in specific subcellular compartments<sup>40–43</sup>. However, when





**Fig. 4 | Neuronal *Pfkfb3* induces an mROS-mediated metabolic-like syndrome that is mimicked by confining *Pfkfb3* expression to MBH neurons.** **a**, Body weight progression in mice of the indicated genotypes fed the HFD (Extended Data Fig. 6b). **b–f**, Food intake (**b**), plasma triglycerides (**c**), free fatty acids (mEq, milliequivalents) (**d**), leptin (**e**) and insulin (**f**) in HFD-fed mice. Data are mean  $\pm$  s.e.m. *P* values are indicated;  $n = 5$  (**b**),  $n = 3$  (**c,e**) or  $n = 4$  (**d,f**) for WT mice;  $n = 9$  (**b**),  $n = 3$  (**c,e**) or  $n = 4$  (**d,f**) for *Camk11a-Pfkfb3* mice;  $n = 4$  (**b**),  $n = 3$  (**c,e**) or  $n = 4$  (**d,f**) for *Camk11a-mCat* mice;  $n = 5$  (**b**),  $n = 3$  (**c,e**),  $n = 4$  (**d**) or  $n = 6$  (**f**) for *Camk11a-Pfkfb3-mCat* mice; one-way ANOVA followed by Bonferroni correction. **g**, Glucose-tolerance test in HFD-fed mice (Extended Data Fig. 6f). **h**, Autophagic flux analysis by western blot for LC3-I, LC3-II and p62 in freshly obtained MBH slices from mice of the indicated genotypes, incubated, or not, with lysosomal inhibitors.  $\beta$ -Actin was used as the loading control (Extended Data Fig. 6g). **i**, Strategy used to express *Pfkfb3* in MBH neurons by stereotaxic injections of AAV expressing, or not, Cre recombinase.

Created with <https://www.biorender.com>. **j**, Novel object-recognition test analysis in WT and MBH-nPfkfb3 mice. Data are mean  $\pm$  s.e.m.,  $n = 7$ ; unpaired Student's *t*-test, two sided. **k**, Body weight progression in WT or MBH neurons in *Pfkfb3*-expressing (MBH-nPfkfb3) mice fed the HFD (Extended Data Fig. 6i). **l**, Food intake in WT or MBH-nPfkfb3 mice fed the HFD. Data are mean  $\pm$  s.e.m. *P* value is indicated ( $n = 3$  mice per condition; unpaired Student's *t*-test, two sided). **m**, Glucose-tolerance test in WT or MBH-nPfkfb3 mice fed the HFD (Extended Data Fig. 6l). **n**, Graphical summary describing the main message of this work. In neurons, low PFKFB3 abundance keeps glycolysis (Glyc) attenuated (which preserves NAD<sup>+</sup>-dependent mitophagy) and boosts the PPP (which regenerates NADPH(H<sup>+</sup>) to prevent redox stress). These mechanisms acting on the hippocampus and on the MBH are required to promote cognition and organismal fitness, respectively. Glucose 6P, glucose 6-phosphate; 6-PG, 6-phosphogluconate. Created with <https://www.biorender.com>.

compared with neurons, adjacent astrocytes robustly consume glucose via glycolysis<sup>44</sup> and fatty acids via  $\beta$ -oxidation<sup>45</sup>, generating lactate and ketone bodies, respectively, which can contribute to satisfying neuronal energy needs<sup>2,46</sup>. It is therefore tempting to speculate that the neurological benefits of the ketogenic diet<sup>47</sup> rely on its ability to sustain the energy demands of weak glycolytic neurons. Thus, neurons are metabolically inflexible cells unable to adapt to the sustained active glycolysis that is linked with neurological and metabolic syndromes,

in which neuron-specific inhibition of PFKFB3 may be considered as a therapeutic opportunity.

## Methods

### Mice

All protocols were performed according to the European Union Directive 86/609/EEC and Recommendation 2007/526/EC, regarding the protection of animals used for experimental and other scientific



purposes, enforced in Spanish legislation under the law 6/2013. Protocols were approved by the Bioethics Committee of the University of Salamanca. All mice used in this study were of the C57BL/6J background. Both male and female mice were used, although most data shown correspond to male mice unless otherwise stated. Mice were bred at the Animal Experimentation Facility of the University of Salamanca in cages (maximum of five animals per cage), and a light–dark cycle was maintained for 12 h. Humidity was 45–65%, and temperature was 20–25 °C. Animals were fed ad libitum with a standard solid diet (Envigo-Harlan Teklad Global 18% Protein Rodent Diet; 18% protein, 3% lipids, 58.7% carbohydrate component, 4.3% cellulose, 4% minerals and 12% humidity) and had free access to water. When indicated, animals were switched to an HFD (D12451, Research Diets; 20% protein, 45% lipids and 35% carbohydrates, plus minerals and vitamins).

### In vivo generation of neuron-specific *Cdh1*<sup>-/-</sup> mice

To inactivate the *Cdh1* gene in neurons of the adult brain, *Cdh1*<sup>lox/lox</sup> mice<sup>12</sup> were mated with mice carrying the gene encoding Cre recombinase under the control of the *CamkIIα* promoter (Jackson Laboratory)<sup>13</sup>, generating *CamkIIα-Cdh1*<sup>-/-</sup> mice.

### In vivo generation of neuron-specific *Pfkfb3*-expressing mice

*Pfkfb3*<sup>lox/+</sup> mice were generated by homologous recombination in the *Rosa26* locus of embryonic stem cells of the C57BL/6J background, where we introduced the full-length cDNA for mouse *Pfkfb3* preceded by a transcriptional stop cassette flanked by two *loxP* sites. This *loxP*-flanked stop signal was incorporated between the CAG promoter and the mouse *Pfkfb3* cDNA (Fig. 1a). To express *Pfkfb3* in neurons in vivo, *Pfkfb3*<sup>lox/+</sup> mice were mated with *CamkIIα-cre* mice to generate *CamkIIα-Pfkfb3* mice. Where indicated, neuron-specific *Pfkfb3*-expressing mice were generated by intravenously transduced adenovirus expressing Cre under control of the *CamkIIα* promoter (AAV-PHP.eB-CamkIIα-Cre) in weaned (-3-week-old) *Pfkfb3*<sup>lox/+</sup> mice; controls were *Pfkfb3*<sup>lox/+</sup> mice transduced with a virus expressing GFP instead of Cre (AAV-PHP.eB-CamkIIα-GFP).

### In vivo generation of neuron-specific *mCat-Pfkfb3*-expressing mice

We first mated *mCat*<sup>lox/+</sup> mice<sup>20</sup> with *Pfkfb3*<sup>lox/+</sup> mice, which generated double-transgenic *Pfkfb3*<sup>lox/+</sup>; *mCat*<sup>lox/+</sup> mice. Next, *Pfkfb3*<sup>lox/+</sup>; *mCat*<sup>lox/+</sup> mice were mated with *CamkIIα-cre* mice to generate *CamkIIα-Pfkfb3-mCat* mice.

### Treatment of mice with nicotinamide mononucleotide

NMN was intraperitoneally administered (100 mg per kg body weight; 200 μl per animal dissolved in phosphate-buffered saline (PBS) as the vehicle) to -4-week-old mice at three injections per week for 1 month. Control mice received an identical volume of the vehicle.

### Neurons in primary culture

Neurons in primary culture were prepared from the cortex of E14.5 embryos<sup>20</sup> of the genotypes *Pfkfb3*<sup>lox/+</sup>; *mCat*<sup>lox/+</sup> and *Pfkfb3*<sup>lox/+</sup>; *mCat*<sup>lox/+</sup>. Littermates were genotyped and used individually. Cell suspensions were seeded at 2.0 × 10<sup>5</sup> cells per cm<sup>2</sup> in poly-D-lysine (10 μg ml<sup>-1</sup>)-coated plastic plates in Neurobasal-A medium supplemented with 2 mM glutamine, 5.5 mM glucose, 0.22 mM pyruvate and 2% antioxidant B27 supplement. Cells were incubated at 37 °C in a humidified 5% CO<sub>2</sub>-containing atmosphere. Seventy-two hours after plating, the medium was replaced with medium containing 2% of the minus-antioxidant (that is, lacking vitamin E, vitamin E acetate, superoxide dismutase, catalase and glutathione) B27 supplement, and cells were transduced with AAV-CMV-Cre-GFP or AAV-CMV-GFP to obtain transgene expression or controls, as indicated, and further incubated with fresh medium until day 7. Immunocytochemical analysis revealed that -99.5% of cells were neurons<sup>48</sup>.

### Genotyping by polymerase chain reaction

For *Pfkfb3*<sup>lox/+</sup> genotyping, a PCR with the following primers was performed: 5'-CGTGATCTGCAACTCCAGTCTTTC-3', 5'-CCCAGATGACTACTTATCTCCCA-3' and 5'-TCCCAGTCATAGCTGCCCTCTTC-3'. PCR conditions were 5 min at 98 °C, 25 cycles of 5 s at 98 °C, 5 s at 60 °C, 20 s at 72 °C and a final extension of 2 min at 72 °C, resulting in an 82-bp band for *Pfkfb3*<sup>lox/lox</sup> mice and a 217-bp band for wild-type mice. Primers for genotyping the *mCat* allele were 5'-CTCCCAAAGTCGCTCTGAGTTGTTATCA-3', 5'-CGATTGTTGGTGTATGTAATACTGTCTGG-3' and 5'-GCAGTGAGAAGAGTACCACCATGAGTCC-3', which yielded a 778-bp band for the wild-type allele and a 245-bp band for the *mCat* allele. PCR conditions were 5 min at 94 °C, 35 cycles of 30 s at 94 °C, 30 s at 65 °C, 3 min at 68 °C and 8 min at 68 °C. PCR products were resolved on a 3% agarose gel using the 1 Kb Plus DNA ladder (Thermo Fisher Scientific).

### Immunomagnetic purification of neurons and astrocytes from the adult brain

The brain (without the cerebellum and the olfactory bulb) was dissociated using the adult mouse brain dissociation kit (Miltenyi Biotec). The tissue, once clean, was fragmented with a sterile scalpel in 2 ml per hemisphere of a disintegration solution (Earle's Balanced Salt Solution, 116 mM NaCl, 5.4 mM KCl, 1.5 mM MgSO<sub>4</sub>, 26 mM NaHCO<sub>3</sub>, 1.01 mM NaH<sub>2</sub>PO<sub>4</sub>·2H<sub>2</sub>O, 4 mM glucose, 10 mg l<sup>-1</sup> phenol red, supplemented with 14.4 μl ml<sup>-1</sup> albumin and 26 μl ml<sup>-1</sup> DNase type I, pH 7.2), and it was trypsinized (10.8 μl ml<sup>-1</sup> trypsin) at 37 °C in a thermostated bath for 5 min, shaking frequently to avoid decantation of the tissue. Next, the suspension was triturated using a 5-ml serological pipette (five times) and further incubated for 10 min with frequent shaking. Trypsin activity was stopped by adding 10% foetal calf serum, before centrifuging the tissue at 700g for 5 min in a microcentrifuge at 4 °C. Once the enzymatically disintegrated tissue was decanted, the pellet was resuspended in a trypsin-free disintegration solution (Earle's Balanced Salt Solution with 13 μl ml<sup>-1</sup> DNase and 20 μl ml<sup>-1</sup> albumin) for trituration using a fire-polished Pasteur pipette. Approximately five passages were performed for a volume of 4 ml per hemisphere. The supernatant was centrifuged for 3 min at 700g, and cells in the pellet were counted. Once a homogeneous suspension of individualized adult neural cells was achieved, cell population separation was performed using MACS Technology with either the astrocyte-specific Anti-ACSA-2 MicroBead Kit or the neuron-specific Neuron Isolation Kit, according to the manufacturer's protocol (MACS Technology). We confirmed the identity of the isolated fractions by western blotting for neuronal (TUJ1)- or astrocytic (GFAP)-specific markers<sup>48</sup>.

### In vivo viral transduction

This was carried out using a validated AAV strategy<sup>49</sup>. Essentially, AAV particles of the PHP.eB capsid (serotype), known to efficiently transduce the central nervous system via intravenous injection<sup>50</sup> and expressing Cre recombinase driven by the neuron-specific hSyn promoter (AAV-PHP.eB-hSyn-Cre-GFP), were administered intravenously (50-μl aliquots of a PBS solution containing 0.001% Pluronic F-68, Sigma-Aldrich and 5 × 10<sup>10</sup> viral genomes) through the retro-orbital sinus to 2-month-old *Pfkfb3*<sup>lox/+</sup> mice under brief sevoflurane anaesthesia (Sevorane, Abbot, at 6% for initiation followed by -3% for maintenance in air with supplementary O<sub>2</sub> and NO<sub>2</sub> at 0.4 and 0.8 l min<sup>-1</sup>, respectively, using a gas distribution column (Hersill H-3) and a vaporiser (InterMed Penlon Sigma Delta). We used the retro-orbital sinus intravenous route because of the higher success rate observed when compared with the tail or temporal ones<sup>51</sup>. To obtain controls, *Pfkfb3*<sup>lox/+</sup> siblings received equivalent amounts of the same AAV particles that did not harbour Cre recombinase. Mice were used from 4 weeks after AAV injections.

### Stereotaxic injections

Nine-week-old *Pfkfb3*<sup>lox/+</sup> mice were anaesthetized by inhalatory induction (4%) and maintained (2.5%) with sevoflurane (Sevorane, Abbot) in

a gas mixture of 70% N<sub>2</sub>O and 30% O<sub>2</sub>, using a gas distribution column (Hersill H-3) and a vaporiser (InterMed Penlon Sigma Delta). Mice were placed in a stereotaxic alignment system (model 1900, David Kopf Instruments) complemented with a stereomicroscope (Nikon SMZ645) and a fibre optic cold light source (Schott KL1500 compact). Injection was performed into the arcuate nucleus at coordinates AP = -2.00 mm, ML = +0.25 mm and DV = -5.5 mm from the bregma using a 5- $\mu$ l Hamilton syringe with a (Microliter 65RN) 26S needle (type 2 tip). Either 0.5  $\mu$ l of AAV10-CamkII $\alpha$ -Cre-GFP or AAV10-CamkII $\alpha$ -GFP (2.75  $\times$  10<sup>12</sup> viral genomes) was injected using a 5- $\mu$ l Hamilton syringe at a rate of 0.25  $\mu$ l min<sup>-1</sup> during 2 min with a mini-pump (UltraMicroPump III, World Precision Instruments). The same volume of the dye Evans blue (Sigma) was injected in the same manner to confirm the injection site. At the end of the injection, the syringe was left in place for 5 min before being slowly removed to prevent reflux. The skin was sutured, and mice were allowed to recover in a warming cabinet (Plactronic Digital, 25  $\times$  60, JP Selecta).

### Mouse perfusion, immunohistochemistry and image analysis

Animals were deeply anaesthetized by intraperitoneal injection of a mixture (1:4) of xylazine hydrochloride (Rompun, Bayer) and ketamine hydrochloride-chlorbutol (Imalgene, Merial) using 1 ml of the mixture per kg body weight and then perfused intra-aortically with 0.9% NaCl followed by 5 ml per g body weight of Somogy's fixative (4% (wt/vol) paraformaldehyde, 0.2% (wt/vol) picric acid in 0.1 M phosphate buffer, pH 7.4). After perfusion, brains were dissected out sagittally in two parts and postfixed, using Somogy's fixative, for 2 h at room temperature. Brain blocks were then rinsed successively for 10 min, 30 min and 2 h with 0.1 M PBS (pH 7.4) and sequentially immersed in 10%, 20% and 30% (wt/vol) sucrose in PBS until they sank. After cryoprotection, 10-, 20- and 40-mm-thick sagittal sections were obtained with a freezing-sliding cryostat (Leica, CM1950 AgProtect).

Sections were rinsed with 0.1 M PBS three times each for 10 min and then incubated with (1) 1:1,000 anti-NeuN (A-60, Merck Millipore), 1:300 anti-TUJ1 (T2200, Sigma), 1/500 anti-GFAP (G6171, Sigma), 1/100 anti-PFKFB3 (H00005209-M08, Novus Biologicals), 1/500 anti-cyclinB1 (sc-7393, Santa Cruz Biotechnology), 1/500 anti-ROCK2 (sc-398519, Santa Cruz Biotechnology) antibodies in 0.2% Triton X-100 (Sigma-Aldrich) and 5% goat serum (Jackson ImmunoResearch) in 0.1 M PBS for 72 h at 4 °C and (2) the fluorophore-conjugated secondary antibodies goat anti-rabbit-Cy2 (111-225-144, Jackson ImmunoResearch, 1/500) or goat anti-mouse-Cy5 (115-175-003, Jackson ImmunoResearch, 1/500) in 0.05% Triton X-100 and 2% goat serum in 0.1 M PBS for 2 h at room temperature<sup>14</sup>. After rinsing with PBS, sections were mounted with Fluoromount (Sigma) aqueous mounting medium. Confocal images were taken with a scanning laser confocal microscope ('Spinning Disk' Roper Scientific Olympus IX81) with three lasers (405, 491 and 561 nm) and equipped with a  $\times$ 63 PL Apo oil-immersion objective for high-resolution imaging and a device digital camera (Evolve, Photometrics).

Dendrite integrity in the hippocampus was assayed by analysing the density of TUJ1-positive dendrites in three sections per animal. Fluorescence eight-bit images were acquired as z stacks and were exported into ImageJ in TIFF format for processing. Images were converted to greyscale eight-bit images, and brightness and contrast were adjusted using the ImageJ 'auto' function. All TUJ1-positive dendrites and GFAP-positive cells were automatically delineated using the 'auto setting threshold' (default method) and 'dark background' functions of ImageJ. Thresholded images were subsequently quantified as percent area (area fraction) using the 'analyze-measure' function, which represents the percentage of pixels in the image that have been highlighted (percentage area)<sup>14</sup>. Values are mean  $\pm$  s.e.m. from 15 measurements.

### Terminal deoxynucleotidyl transferase dUTP nick end-labelling assay

The terminal deoxynucleotidyl transferase dUTP nick end-labelling (TUNEL) assay was performed on 20- $\mu$ m brain sections, following the

manufacturer's protocol (Roche Diagnostics). Brain sections, fixed as above, were pre-incubated in TUNEL buffer containing 1 mM CoCl<sub>2</sub>, 140 mM sodium cacodylate and 0.3% Triton X-100 in 30 mM Tris buffer, pH 7.2, for 30 min. After incubation at 37 °C with the TUNEL reaction mixture containing terminal deoxynucleotidyl transferase (800 U ml<sup>-1</sup>) and a nucleotide mixture (1  $\mu$ M) for 90 min, sections were rinsed with PBS and counterstained with Cy3-streptavidin (Jackson ImmunoResearch Laboratories)<sup>52</sup>.

### Plasma determination of lipids and hormones

For serum triglyceride (T2449, Sigma-Aldrich) and fatty acid (NEFA-HR, Wako Pure Chemical) analyses, we used 10  $\mu$ l of undiluted serum; for insulin (A05105, SPI Bio) and leptin (A05176, SPI Bio) levels, the serum was diluted four times and we used 50  $\mu$ l and 100  $\mu$ l, respectively. We used the protocols according to the manufacturer's instructions.

### Glucose-tolerance test

This analysis was performed by intraperitoneally injecting D-glucose at 2 g per kg body weight (Sigma) into mice that had been previously fasted for 16 h. Blood was collected from tail bleeds every 30-min to 3-h period, and the amount of plasma glucose was determined using a glucometer (FreeStyle Optium Neo, Abbot). Area-under-the-curve values were determined using GraphPad Prism 8 software.

### Mitochondrial reactive oxygen species

Mitochondrial ROS levels were determined with the fluorescent probe MitoSOX (Life Technologies). Cultured cells or adult brain cell suspensions were incubated with 2  $\mu$ M MitoSOX for 30 min at 37 °C in a 5% CO<sub>2</sub> atmosphere in HBSS buffer (134.2 mM NaCl, 5.26 mM KCl, 0.43 mM KH<sub>2</sub>PO<sub>4</sub>, 4.09 mM NaHCO<sub>3</sub>, 0.33 mM Na<sub>2</sub>HPO<sub>4</sub>·2H<sub>2</sub>O, 5.44 mM glucose, 20 mM HEPES and 20 mM CaCl<sub>2</sub>·2H<sub>2</sub>O, pH 7.4). The cells were then washed with PBS (136 mM NaCl, 2.7 mM KCl, 7.8 mM Na<sub>2</sub>HPO<sub>4</sub>·2H<sub>2</sub>O, 1.7 mM KH<sub>2</sub>PO<sub>4</sub>, pH 7.4) and collected by trypsinization. MitoSOX fluorescence intensity was assessed by flow cytometry (FACSCalibur flow cytometer, BD Biosciences) and expressed in AU.

### Hydrogen peroxide determination

For H<sub>2</sub>O<sub>2</sub> assessments, Amplex Red (Life Technologies) was used. Cells were trypsinized and incubated in KRPG buffer (145 mM NaCl, 5.7 mM Na<sub>2</sub>HPO<sub>4</sub>, 4.86 mM KCl, 0.54 mM CaCl<sub>2</sub>, 1.22 mM MgSO<sub>4</sub>, 5.5 mM glucose, pH 7.35) in the presence of 9.45  $\mu$ M Amplex Red containing 0.1 U ml<sup>-1</sup> horseradish peroxidase. Luminescence was recorded for 2 h at 30-min intervals using a Varioskan Flash reader (Thermo Scientific) (excitation, 538 nm; emission, 604 nm). Slopes were used for calculating the rate of H<sub>2</sub>O<sub>2</sub> formation.

### Mitochondrial membrane potential

The mitochondrial membrane potential ( $\Delta\psi_m$ ) was assessed through two different methodological approaches: (1) MitoProbe DiIC<sub>1</sub>(5) (50 nM, Life Technologies) by flow cytometry (FACSCalibur flow cytometer, BD Biosciences) and expressed in AU. For this purpose, cultured cells or adult brain cell suspensions were incubated with the probe for 30 min at 37 °C in PBS.  $\Delta\psi_m$  was obtained after subtraction of the potential value determined in the presence of carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazine (10  $\mu$ M, 15 min) for each sample; (2) TMRM (10 nM, Sigma-Aldrich) with cyclosporine H (1  $\mu$ M, Sigma-Aldrich) by confocal microscopy using the Operetta CLS microscope (PerkinElmer). For this aim, primary neurons were seeded into 96-well plates (PerkinElmer) and pre-incubated in KRPG buffer (145 mM NaCl, 5.7 mM Na<sub>2</sub>HPO<sub>4</sub>, 4.86 mM KCl, 0.54 mM CaCl<sub>2</sub>, 1.22 mM MgSO<sub>4</sub>, 5.5 mM D-glucose, pH 7.35). Furthermore, cells were loaded with the dye TMRM (10 nM) and cyclosporine H (1  $\mu$ M) in the Operetta CLS microscope (30 min at 37 °C in a 5% CO<sub>2</sub> atmosphere), and confocal images were acquired with a  $\times$ 40, 1.4-NA objective (PerkinElmer). The mitochondrial uncoupler carbonyl cyanide 4-(trifluoromethoxy)

phenylhydrazine (10  $\mu\text{M}$ , Sigma-Aldrich) was added for 15 min as a control for mitochondrial depolarization. Finally, images were analysed using Harmony software (PerkinElmer).

### Flow cytometric analysis of apoptotic cell death

Adult brain cell suspensions from the hippocampus or the MBH were incubated with APC-conjugated annexin V and 7-aminoactinomycin D (7-AAD) (Becton Dickinson Biosciences) to quantitatively determine the percentage of apoptotic neurons (Syn-GFP<sup>+</sup>) by flow cytometry. Brain cell suspensions were stained with annexin V-APC and 7-AAD in binding buffer (100 mM HEPES, 140 mM NaCl, 2.5 mM CaCl<sub>2</sub>), according to the manufacturer's instructions, and 10<sup>4</sup> cells were analysed, in three replicates per condition, on a FACSCalibur flow cytometer (15-mW argon ion laser, CellQuest software, Becton Dickinson Biosciences), using FL4 and FL3 channels, respectively. Annexin<sup>+</sup> and 7-AAD<sup>-</sup> cells were considered apoptotic. The analyser threshold was adjusted on the flow cytometer channel to exclude most of the subcellular debris to reduce background noise owing to neurite disruption during neuronal resuspensions. Data were expressed as percentages.

### Determination of metabolic fluxes

To assess glycolysis, PPP and lipogenesis fluxes, we used radiometric approaches. To do this, neurons were seeded in 8-cm<sup>2</sup> flasks with a hanging microcentrifuge tube containing either 1 ml benzethonium hydroxide (Sigma) (for <sup>14</sup>CO<sub>2</sub> equilibration) or 1 ml water (for <sup>3</sup>H<sub>2</sub>O equilibration). All incubations were carried out in KRPG (NaCl, 145 mM; Na<sub>2</sub>HPO<sub>4</sub>, 5.7 mM; KCl, 4.86 mM; CaCl<sub>2</sub>, 0.54 mM; MgSO<sub>4</sub>, 1.22 mM; pH 7.35) containing 5 mM D-glucose at 37 °C in the air-thermostated chamber of an orbital shaker. To ensure adequate oxygen supply for oxidative metabolism throughout the incubation period, flasks' atmosphere was gassed with carbogen (5% CO<sub>2</sub> and 95% O<sub>2</sub>) before sealing with a rubber cap. To measure the carbon flux from glucose to CO<sub>2</sub>, cells were incubated in KRPG (5 mM glucose) buffer with 0.25  $\mu\text{Ci ml}^{-1}$  of [6-<sup>14</sup>C]glucose or [1-<sup>14</sup>C]glucose<sup>3</sup>. Incubations were terminated after 90 min by the addition of 0.2 ml 20% perchloric acid (Merck Millipore), and, after a further 60 min, the tube containing benzethonium hydroxide (with the trapped <sup>14</sup>CO<sub>2</sub>) was used to determine radioactivity using a liquid scintillation analyser (Tri-Carb 4810TR, PerkinElmer). The flux of lipogenesis was measured by assaying the rate of [U-<sup>14</sup>C]glucose incorporation into lipids with a similar strategy using 3  $\mu\text{Ci ml}^{-1}$  of D-[6-<sup>14</sup>C]glucose in KRPG buffer (5 mM D-glucose) for 3 h<sup>53</sup>. After incubations were terminated with 0.2 ml 20% perchloric acid, the cells were washed twice with PBS, recollected and centrifuged at 500g for 5 min. The supernatant was discarded, and the pellet was resuspended in 500  $\mu\text{l}$  of a chloroform-methanol mixture (2:1, vol/vol)<sup>54</sup> for 16 h at -20 °C. The extract was washed with 250  $\mu\text{l}$  of 0.3% (wt/vol) NaCl saturated with chloroform. The samples were centrifuged at 1,500g for 15 min, and the aqueous phase, containing cellular hydrosoluble components, was discarded. Later, this same process was repeated, this time using 250  $\mu\text{l}$  of 0.3% (wt/vol) NaCl saturated with chloroform plus 180  $\mu\text{l}$  methanol. The resulting chloroformic phase was passed to a new tube. Every step was performed at 4 °C. An aliquot of 50  $\mu\text{l}$  of the organic phase containing the lipid fraction was used for the measurement of radioactivity incorporated into total lipids. Glycolytic flux was measured by assaying the rate of <sup>3</sup>H<sub>2</sub>O production from [3-<sup>3</sup>H]glucose using a similar strategy with 3  $\mu\text{Ci ml}^{-1}$  D-[3-<sup>3</sup>H]glucose in KRPG buffer (5 mM D-glucose) for 120 min<sup>3</sup>. After incubations were terminated with 0.2 ml 20% perchloric acid, the cells were further incubated for 72 h to allow for <sup>3</sup>H<sub>2</sub>O equilibration with water present in the central microcentrifuge tube. The <sup>3</sup>H<sub>2</sub>O level was then measured by liquid scintillation counting (Tri-Carb 4810TR, PerkinElmer). Specific radioactivity was used for calculations. Under these experimental conditions, 75% of the produced <sup>14</sup>CO<sub>2</sub> and 28% of the produced <sup>3</sup>H<sub>2</sub>O were recovered and taken into account for the calculations<sup>3</sup>.

### Lactate and glucose determinations

Lactate concentrations were measured in the culture medium spectrophotometrically<sup>3</sup> by determination of increments in the absorbance of the samples at 340 nm in a mixture containing 1 mM NAD<sup>+</sup>, 8.25 U lactate dehydrogenase in 0.25 M glycine, 0.5 M hydrazine and 1 mM ethylenediaminetetraacetic acid (EDTA) buffer, pH 9.5. D-glucose was measured spectrophotometrically<sup>3</sup> by reading the increase in NADPH(H<sup>+</sup>) absorbance at 340 nm produced in two coupled reactions catalysed by hexokinase and glucose-6-phosphate dehydrogenase (G6PD) (Roche Diagnostics) after 10 min of incubation.

### Malate-aspartate and glycerol phosphate shuttles

These were determined both by the brain concentrations of their component metabolites (aspartate, glutamate,  $\alpha$ -ketoglutarate and malate for the malate-aspartate shuttle; glycerol 3-phosphate and dihydroxyacetone phosphate for the glycerol phosphate shuttle) and by their activities as assessed by the following ratios of the <sup>13</sup>C-enriched components after [U-<sup>13</sup>C]glucose administration, namely: malate-aspartate and glutamate- $\alpha$ -ketoglutarate (malate-aspartate shuttle) and glycerol 3-phosphate-(2- and 3-phosphoglycerate) (glycerol phosphate shuttle). The sum of 2- and 3-phosphoglycerate was used as a proxy of dihydroxyacetone phosphate, which was not detected by MS.

### Oxygen-consumption rate assessment

OCRs of primary neurons were measured in real-time in an XFe24 Extracellular Flux Analyzer (Seahorse Bioscience, Seahorse Wave Desktop software 2.6.1.56). This equipment measures the extracellular medium O<sub>2</sub> flux changes of cells seeded in 24-well plates. Regular cell medium was removed, and cells were washed twice with DMEM running medium (XF assay modified, supplemented with 5 mM glucose, 2 mM L-glutamine, 1 mM sodium pyruvate, 5 mM HEPES, pH 7.4) and incubated at 37 °C without CO<sub>2</sub> for 30 min to allow cells to pre-equilibrate with the assay medium. Oligomycin, FCCP and a mixture of rotenone and antimycin, diluted in DMEM running medium, were loaded into port A, port B and port C, respectively. Final concentrations in XFe24 cell culture microplates were 1  $\mu\text{M}$  oligomycin, 2  $\mu\text{M}$  FCCP, 1  $\mu\text{M}$  rotenone and 1  $\mu\text{M}$  antimycin. The sequence of measurements was as follows. The basal level of the OCR was measured three times, and then reagents were injected into port A and mixed for 3 min; after, the OCR was measured three times for 3 min. The same protocol was repeated with port B and port C. OCR was measured after each injection to determine mitochondrial or non-mitochondrial contribution to the OCR. All measurements were normalized to average three measurements of the basal (starting) level of the cellular OCR of each well. Each sample was measured in three to five replicates. Experiments were repeated three times in biologically independent culture preparations. Non-mitochondrial OCR was determined by the OCR after injecting antimycin and rotenone. Maximal respiration was determined by the maximum OCR rate after FCCP injection minus the non-mitochondrial OCR. ATP production was determined by the last OCR measurement before oligomycin injection minus the minimum OCR measurement after oligomycin injection.

### Activity of mitochondrial complexes

Cells were collected and suspended in PBS (pH 7.0). After three cycles of freeze-thawing, to ensure cellular disruption, CI, complex II-III and citrate synthase activities were determined. Rotenone-sensitive NADH-ubiquinone oxidoreductase activity (CI)<sup>55</sup> was measured in KH<sub>2</sub>PO<sub>4</sub> (20 mM, pH 7.2) in the presence of 8 mM MgCl<sub>2</sub>, 2.5 mg ml<sup>-1</sup> BSA, 0.15 mM NADH and 1 mM KCN. Changes in absorbance at 340 nm (30 °C) ( $\epsilon = 6.81 \text{ mM}^{-1} \text{ cm}^{-1}$ ) were recorded after the addition of 50  $\mu\text{M}$  ubiquinone and 10  $\mu\text{M}$  rotenone. Deactive CI was determined after *N*-ethylmaleimide (NEM) treatment of cell homogenates (10 mM, 15 min, 15 °C). CI activity in the presence of NEM exclusively reflects the active form of CI, as NEM blocks the transition from the deactive



conformation to the active conformation. Complex II–III (succinate–cytochrome c oxidoreductase) activity<sup>56</sup> was determined in the presence of 100 mM phosphate buffer with 0.6 mM EDTA(K<sup>+</sup>), 2 mM KCN and 200  $\mu$ M cytochrome c. Changes in absorbance were recorded (550 nm, 30 °C) ( $\epsilon = 19.2 \text{ mM}^{-1} \text{ cm}^{-1}$ ) after the addition of 20 mM succinate and 10  $\mu$ M antimycin A. Citrate synthase activity<sup>57</sup> was measured in the presence of 93 mM Tris-HCl, 0.1% (vol/vol) Triton X-100, 0.2 mM acetyl-CoA, 0.2 mM 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB); the reaction was started with 0.2 mM oxaloacetate, and the absorbance was recorded at 412 nm (30 °C) ( $\epsilon = 13.6 \text{ mM}^{-1} \text{ cm}^{-1}$ ).

#### Determination of total, reduced and oxidized glutathione

Cells were lysed with 1% (wt/vol) sulfosalicylic acid and centrifuged at 13,000g for 5 min at 4 °C, and the supernatants were used for determining total glutathione (GSH concentration plus twice the concentration of GSSG), by using GSSG (0–50  $\mu$ M) as a standard. Total glutathione was measured in reaction buffer (0.1 mM NaH<sub>2</sub>PO<sub>4</sub>, 1 mM EDTA, 0.3 mM DTNB, 0.4 mM NADPH and glutathione reductase at 1 U ml<sup>-1</sup>, pH 7.5) by recording the increase in absorbance at 405 nm after the reaction of GSH with DTNB for 2.5 min at 15-s intervals using a Varioskan Flash reader (Thermo Fisher). GSSG levels were quantified after derivatization of GSH with 2-vinylpyridine, by using similarly treated GSSG standards (0–5  $\mu$ M), and results are expressed as the GSSG/GSH ratio.

#### NAD<sup>+</sup> determination

To determine oxidized NAD<sup>+</sup> levels, we used a bioluminescent NAD/NADH-Glo Assay (Promega). Neurons were seeded in 96-well plates and incubated for 30–60 min with NAD/NADH-Glo Detection Reagent containing reductase, reductase substrate, NAD cycling enzyme and NAD cycling substrate, according to the manufacturer's recommendations. Detergent was present in the reagent-lysed cells, allowing detection of total cellular NAD<sup>+</sup>. Due to the cycling of the coupled enzymatic reactions, the light signal will continue to increase after adding the reagent to the sample. The luminescent signal remains proportional to the starting amount of NAD<sup>+</sup> within the linear range of the assay. To measure only the oxidized (NAD<sup>+</sup>) form, it is necessary to treat cells with 25  $\mu$ l of 0.4 M HCl to destroy the reduced forms (NADH). Results are expressed as mean  $\pm$  s.e.m. (pmol per mg protein) using the standard curve (0–400 nM).

#### Sirtuin activity assay

To evaluate sirtuin activity with either HDAC or monoribosyltransferase activity, we used the fluorometric Sirtuin Activity Assay Kit (K324-100, BioVision). Neurons were seeded in 96-well plates and lysed with 300  $\mu$ l of cold homogenization buffer containing protease inhibitor cocktail. Next, lysates were transferred to a cold microcentrifuge tube and agitated on a rotary shaker at 4 °C for 15 min. Finally, 50  $\mu$ l cell homogenate was incubated at 37 °C for 30–60 min with 40  $\mu$ l reaction mix. After incubation, 10  $\mu$ l developer was added to each sample except the standards (p53–AFC substrate, 0–1,000 pmol per well), and samples were incubated for 15 min at 37 °C. Next, fluorescence was recorded (excitation and emission, 400 and 505 nm) in endpoint mode. In this protocol, the acetylated p53–AFC substrate is deacetylated by sirtuins in the presence of NAD<sup>+</sup> to generate the deacetylated p53–AFC substrate, nicotinamide and *O*-acetyl-ADP-ribose. Cleavage of the deacetylated p53–AFC substrate by the developer releases the fluorescent group (AFC, 400 and 505 nm). Trichostatin A is added to the reaction to specifically inhibit HDACs in samples.

#### Fructose-2,6-bisphosphate determination

For F26BP determination, cells were lysed in 0.25 M NaOH and centrifuged (20,000g, 20 min). An aliquot of the homogenate was used for protein determination, and the remaining sample was heated at 80 °C (5 min) and centrifuged (20,000g, 10 min, 4 °C), and the resulting supernatant was used for enzymatic determination of F26BP

concentrations using F26BP standards, as previously described<sup>58</sup>. The F26BP standard was prepared by incubating a 20-mM solution of D-fructose-1,2-cyclic 6-bisphosphate (Sigma, 68872) in 0.5 M NaOH at 37 °C for 30 min. To determine F26BP levels, 20  $\mu$ l of the supernatant was diluted 1:20 in 0.05 M HCl. In parallel, a non-acidified reaction was carried out by diluting the supernatant 1:10 in 0.05 M NaCl. After a 10-min incubation at room temperature, which quantitatively converts F26BP into F6P, the samples were neutralized with 0.1 M NaOH and used to determine F6P in a buffer containing 25 mM HEPES (pH 8.2), 25 mM KCl, 2.5 mM magnesium acetate, 1 mM dithiothreitol and 0.25 mM NADP<sup>+</sup> in the presence of G6PD and phosphoglucose isomerase. F26BP relative levels in the samples were assessed by the coupled enzymatic activities of PFK1 (Sigma, F2258) in the presence of 1 mM F6P (Sigma, F3627) and 0.5 mM pyrophosphate (Sigma, P8010), aldolase (Sigma, A8811) and triosephosphate isomerase or glycerol-3-phosphate dehydrogenase (Sigma, G1881). This reaction generates glycerol 3-phosphate and oxidizes NADH (Sigma, N8129), producing a reduction in the absorbance at 340 nm that is monitored spectrophotometrically. F26BP concentrations are calculated in the samples by comparing the fold activation that they cause on PFK1 activity compared against an F26BP standard curve.

#### Protein determination

Protein samples were quantified with the BCA Protein Assay Kit (Thermo) using BSA as a standard.

#### Western blotting

Cells were lysed in RIPA buffer (1% sodium dodecyl sulphate, 10 mM EDTA, 1% (vol/vol) Triton X-100, 150 mM NaCl and 10 mM Na<sub>2</sub>HPO<sub>4</sub>, pH 7.0), supplemented with protease inhibitor mixture (Sigma), 100  $\mu$ M phenylmethylsulfonyl fluoride and phosphatase inhibitors (1 mM *o*-vanadate). Samples were boiled for 5 min. Aliquots of cell lysates (40–60  $\mu$ g of protein) were subjected to SDS–PAGE on an 8–15% (vol/vol) acrylamide gel (Mini-PROTEAN, Bio-Rad) including the PageRuler Prestained Protein Ladder (Thermo). The resolved proteins were transferred electrophoretically to nitrocellulose membranes (0.2  $\mu$ m, Bio-Rad). Membranes were blocked with 5% (wt/vol) low-fat milk in TTBS (20 mM Tris, 150 mM NaCl and 0.1% (vol/vol) Tween-20, pH 7.5) for 1 h. After blocking, membranes were immunoblotted with primary antibodies overnight at 4 °C. After incubation with horseradish peroxidase-conjugated goat anti-mouse IgG–HRP (170-6516, Bio-Rad, 1/10,000), rabbit anti-goat IgG–HRP (sc-2768, Santa Cruz, 1/10,000) and goat anti-rabbit IgG–HRP (170-6515, Bio-Rad, 1/10,000) antibodies, membranes were immediately incubated with WesternBright ECL from the enhanced chemiluminescence kit (Advanta) or SuperSignal West Femto substrate (Thermo) before exposure to Fuji Medical X-Ray film (Fujifilm), and the autoradiograms were scanned. At least three biologically independent replicates were always performed, although only one representative western blot is shown in the main figures. The protein abundances of all western blots per condition were measured by densitometry of the bands on the films using ImageJ 1.48u4 software (National Institutes of Health) and were normalized to that of the loading control protein. The resulting values were used for statistical analysis. Uncropped scans of western blots replicates are shown in the source data.

#### Primary antibodies for western blotting

Immunoblotting was performed with anti-LC3B (1/1,000) (2775, Cell Signaling), anti-p62 (1/1,000) (P0067, Sigma), anti-ATG7 (1/1,000) (2631, Cell Signaling), anti-acetylated lysine (1/1,000) (9441, Cell Signaling), anti-cyclin B1 (clone D-11, sc-7393, Santa Cruz Biotechnology, 1/500), anti-ROCK2 (clone D-11, sc-398519, Santa Cruz Biotechnology, 1/500), anti-PLIN2 (ab52356, Abcam, 1/500), anti-beclin (1/1,000) (3495, Cell Signaling), anti-TOMM20 (1/1,000) (ab56783, Abcam) anti-PFKFB3 (1/500) (H00005209-M08, Novus Biologicals), anti-VDAC (1/1,000)



(PC548, Calbiochem), anti-heat-shock protein 60 (HSP60) (1/1,000) (ab46798, Abcam), anti-NDUFS1 (1/500) (sc-50132, Santa Cruz Biotechnology), anti-NDUFA9 (1/1,000) (ab14713, Abcam), anti-UQCRC2 (1/1,000) (ab14745, Abcam), anti-SDHA (1/1,000) (ab14715, Abcam), anti-ATP $\beta$  (1/1,000) (MS503, MitoSciences), anti-GFAP (1/500) (G6171, Sigma), anti-TUJ1 (1/300) (T2200, Sigma) and anti- $\beta$ -actin (1/30,000) (A5441, Sigma) antibodies.

### Mitochondrial isolation

To obtain the mitochondrial fraction, cell pellets were frozen at  $-80^{\circ}\text{C}$  and homogenized (10–12 strokes) in a glass–Teflon Potter–Elvehjem homogeniser in buffer A (83 mM sucrose and 10 mM MOPS, pH 7.2). The same volume of buffer B (250 mM sucrose and 30 mM MOPS) was added to the sample, and the homogenate was centrifuged (1,000g, 5 min) to remove unbroken cells and nuclei. Centrifugation of the supernatant was then performed (12,000g, 3 min) to obtain the mitochondrial fraction, which was washed with buffer C (320 mM sucrose, 1 mM EDTA and 10 mM Tris-HCl, pH 7.4)<sup>48</sup>. Mitochondria were suspended in buffer D (1 M 6-aminohexanoic acid and 50 mM Bis-Tris-HCl, pH 7.0).

### Blue native gel electrophoresis

For the assessment of CI organization, digitonin-solubilized (4 g per g) mitochondria (10–50  $\mu\text{g}$ ) were loaded in NativePAGE Novex 3–12% (vol/vol) gels (Life Technologies). After electrophoresis, in-gel NADH dehydrogenase activity was evaluated, allowing the identification of individual CI and CI-containing supercomplex bands due to the formation of purple precipitate at the location of CI<sup>48</sup>. Briefly, gels were incubated in 0.1 M Tris-HCl buffer (pH 7.4), 1 mg ml<sup>-1</sup> nitro blue tetrazolium and 0.14 mM NADH. Next, a direct electrotransfer was performed, followed by immunoblotting for mitochondrial CI with anti-NDUFS1 antibody (1/500) (sc-50132, Santa Cruz Biotechnology), anti-NDUFA9 antibody (1/1,000) (ab14713, Abcam), anti-complex II antibody SDHA (1/1,000) (ab14715, Abcam), anti-complex III antibody UQCRC2 (1/1,000) (ab14745, Abcam), anti-complex IV antibody MTCO4 (1/1,000) (ab14705, Abcam) and anti-complex V antibody ATP $\beta$  (1/1,000) (MS503, MitoSciences). Direct transfer of BNGE was performed after soaking the gels for 20 min ( $4^{\circ}\text{C}$ ) in carbonate buffer (10 mM NaHCO<sub>3</sub>, 3 mM Na<sub>2</sub>CO<sub>3</sub>·10H<sub>2</sub>O, pH 9.5–10). Protein transfer to polyvinylidene fluoride membranes was carried out at 300 mA and 60 V for 1.5 h at  $4^{\circ}\text{C}$  in carbonate buffer.

### Autophagic flux measurement

To analyse the autophagy pathway, primary neurons or MBH slices were incubated in the absence or the presence of inhibitors of lysosomal proteolysis, leupeptin (100 mM) and ammonium chloride (20 mM), for 2 h. Cells or tissues were lysed and immunoblotted for LC3-II, p62 and beclin 1 to assess autophagy and for TOMM20 and VDAC to assess mitophagic flux.

### Metabolomics analysis

One hemisphere from 5–6-month-old *Camk1 $\alpha$ -Pfkfb3* mice or wild-type mice ( $n = 6$  for each condition) was snap frozen in liquid nitrogen and used for untargeted metabolomic analysis (Metabolon). Ultra-high-performance liquid chromatography–tandem mass spectroscopy analysis detected 567 metabolites. Raw data were extracted, peak identified, processed for quality control, curated and normalized by the Metabolon service. Peaks were quantified with the area under the curve. For studies spanning multiple days, a data-normalization step was performed to correct variation resulting from instrument interday tuning differences. Essentially, each compound was corrected in run day blocks by registering the medians to equal one (1.00) and normalizing each data point proportionately. Following log<sub>2</sub> transformation and imputation of missing values, with the minimum observed value for each compound, Welch's two-sample  $t$ -tests were used to identify compounds with significantly different concentrations

between experimental groups. Metabolites labelled as xenobiotics were discarded, resulting in a total of 555 metabolites included in the final analysis. Given the high false discovery rate, metabolites were filtered according to several criteria other than the  $q$  value. Such criteria included (1) biological relevance given the genetic background context, (2) inclusion in a common pathway with a highly significant compound, (3) residing in a similar functional biochemical family with other significant compounds or (4) correlation with other experimental *in vivo* approaches, namely, magnetic resonance spectroscopy and MS. Graphs corresponding to statistical analysis were made with GraphPad Prism 8.0 software and the online tool MetaboAnalyst 5.0 (as of February 2023).

### AZ67 *in vivo* administration

AZ67 (Tocris) for *in vivo* usage was dissolved in 20% (wt/vol) PEG 200 in PBS to a concentration of 20 mM. Vehicle- and AZ67-treated *Cln7<sup>Δex2</sup>* mice were used for this experiment. The cannula was inserted intracerebroventricularly at the age of 8 weeks and, after at least 15 d of recovery, we injected AZ67 at the dose identified previously (1 nmol per mouse) every 24 h<sup>10</sup>. The duration of the experiment was determined by the presence of hindlimb claspings in *Cln7<sup>Δex2</sup>* vehicle-treated mice, this being at 2.5 months. Weight gain of the animals was monitored during this period.

### Behavioural tests

Mice (3 or 8 months old) were left to acclimatize in the room for not less than 30 min at the same time slot of the day (14:00–20:00). Tracking was carried out one at a time, and the apparatus was carefully cleaned with 70% ethanol between trials to remove any odour cues. An ANY-box core was used, which contained a light grey base and an adjustable perpendicular stick holding a camera and an infrared photo-beam array to track animal movement and to detect rearing behaviour, respectively. Mouse movements were tracked with ANY-maze software and the ANY-maze interface to register all parameters described subsequently. For the open-field test, a 40-cm  $\times$  40-cm  $\times$  35-cm ( $w \times d \times h$ ) black infrared transparent Perspex insert was used, and the arena was divided into three zones, namely, border (8 cm wide), centre (16% of total arena) and intermediate (the remaining area). The test lasted for 10 min; the distance travelled and the time spent in each zone were measured.

The rotarod test (rotarod apparatus, model 47600, Ugo Basile) was used to analyse motor balance and coordination. Mice were previously trained for 3 consecutive days before testing to establish the animal's baseline. When performing the test, the animals are placed in the cylinder under a constant acceleration of 7.2 rpm. When the test starts, the cylinder starts accelerating until it reaches 40 rpm after 5 min. The time it takes for the animal to fall from the cylinder is recorded.

The treadmill test was used to evaluate endurance (running time) and running speed (slowness). Mice were previously acclimatized for 3 consecutive days (2 h per day) to allow animals to become familiar with the treadmill and to minimize psychological stress. During this period, the electric grid remains off and the belt motor remains on but not moving. After training, animals were submitted to a graded intensity treadmill test (Model 1050 LS Exer3/6, Columbus Instruments). After a warmup period, the treadmill band velocity was increased until the animals were unable to run further. The initial bout of 6 min at 6 m  $\times$  min<sup>-1</sup> was followed by consecutive 2-m  $\times$  min<sup>-1</sup> increments every 2 min. Exhaustion was defined as the third time a mouse could no longer keep pace with the speed of the treadmill and remained on the shock grid for 2 s rather than running. Exercise motivation was provided for all rodents by means of an electronic shock grid at the treadmill rear. However, the electric shock was used sparingly during the test.

To analyse short-term memory, we used the novel object-recognition test (Stoelting) in a 40-cm  $\times$  40-cm  $\times$  35-cm ( $w \times d \times h$ ) core with a black infrared transparent Perspex insert, also tracked with ANY-maze software and the ANY-maze interface to register the

track of the mice. Mice were accustomed to this environment for 10 min during 2 consecutive days, and the test was performed on the third day. Mice were left to explore two identical equidistant cubes for 5 min (the familiarization phase) and returned for 15 min into their cage. One cube was substituted for a sphere of similar size and colour, and mice were returned to the arena to explore the objects for another 5 min (the test phase). To score zone entries that include the exploration of an object, we considered the size of the object (3.8 × 3.8 cm) and the surrounding perimeter (6 × 6 cm). The ability to recognize the sphere as a novel object was determined as the discrimination index (DI), calculated as  $DI = (T_N - T_F)/(T_N + T_F)$ , where  $T_N$  is the time spent exploring the new object (sphere) and  $T_F$  is the time spent exploring the familiar object (cube).

### Magnetic resonance spectroscopy

Localized  $^1\text{H}$  MRS was performed at 11.7 tesla using a 117/16 USR Bruker BioSpec system (Bruker BioSpin) interfaced to an advance III console and operating ParaVision 6.1 under TopSpin software (Bruker BioSpin). After fine-tuning and shimming of the system, water signal FWHM values typically in the 15–25-Hz range were achieved. Scanning started with the acquisition of three scout images (one coronal, one transverse and one sagittal) using a 2D-multiplane T2W RARE pulse sequence with Bruker's default parameters. These images were used to place the spectroscopy voxel of size  $1.5 \times 1.5 \times 2 \text{ mm}^3$  located at the right striatum of the mouse brain or  $2 \times 0.8 \times 2 \text{ mm}^3$  located in the cortex (at the midline of the brain), always with care not to include the ventricles in the voxel (the geometry of the voxel was slightly altered to avoid this event, when necessary). At least two  $^1\text{H}$ -MRS spectra were acquired per scanning session per animal (5-month-old animals). The voxel was repositioned, and shimming adjustments were repeated between acquired spectra, when the spectral resolution of the obtained  $^1\text{H}$  spectrum was not good. For  $^1\text{H}$ -MR, a water-suppressed PRESS sequence was used with the following parameters: echo time, 17.336 ms ( $TE_1 = TE_2 = 8.668 \text{ ms}$ ); repetition time, 2,500 ms; Naverages, 256; acquisition size, 2,048 points; spectral width, 11 ppm (5,498.53 Hz). MR spectra were fitted and quantified using LCModel 6.3-1R<sup>39</sup>.

### Metabolite extraction for LC–MS analysis

Metabolites were extracted from plasma samples (thawed on ice) by adding 1 ml of cold methanol–water (4:1) solution to 20  $\mu\text{l}$  plasma. After thorough mixing and incubation at  $-20^\circ\text{C}$  for 15 min, samples were centrifuged (16,000g, 15 min,  $4^\circ\text{C}$ ). The supernatant was recovered, dried using the miVac Concentrator (Genevac) and resuspended in 150  $\mu\text{l}$  acetonitrile–water (4:1) solution at  $-20^\circ\text{C}$  with 15 mM ammonium acetate. The extract was transferred to LC–MS autosampler vials for analysis. Frozen brains were first freeze–dried and ground to powder using a Mixer Mill MM 400 (Retsch) operated with dry ice. An amount of powder corresponding to 20 mg of fresh brain tissue was then mixed with  $-20^\circ\text{C}$  methanol–acetonitrile–water (2:2:1) solution containing 0.1% formic acid, followed by vortexing for 1 min, incubation at  $-20^\circ\text{C}$  for 15 min and centrifugation (16,000g, 15 min,  $4^\circ\text{C}$ ). The supernatant was recovered, dried and resuspended in 150  $\mu\text{l}$  acetonitrile–water (4:1) solution at  $-20^\circ\text{C}$  with 15 mM ammonium acetate. The extract was transferred to LC–MS autosampler vials for analysis.

### Liquid chromatography–mass spectrometry analysis

LC–MS analyses were performed using an UHPLC Vanquish Flex chromatographic system coupled to an Orbitrap Q Exactive+ mass spectrometer (Thermo Fisher Scientific) operated in negative (ESI $-$ ) or positive (ESI $+$ ) electrospray ionization mode. Metabolites were separated on a P120 HILIC-Z ( $2.1 \times 150\text{-mm}$  i.d.,  $2.7 \mu\text{m}$ ) column (Agilent) at  $30^\circ\text{C}$ . The HILIC solvents were A, acetonitrile–water (9:1) with 15 mM ammonium acetate and B, acetonitrile–water (1:9) with 15 mM ammonium acetate. HILIC separation was performed at  $250 \mu\text{l min}^{-1}$

with the following gradient (minutes, percent B): 0, 15%; 4, 25%; 5.5, 30%; 13.5, 35%; 15.9, 50%. The column was then equilibrated for 10 min at the initial conditions before the next sample was analysed. The injection volume was 2–5  $\mu\text{l}$ . MS analyses were performed in full-scan mode at a resolution of 70,000 (at 400  $m/z$ ) over the  $m/z$  range 60–1,000. Data were acquired with the following source parameters: capillary temperature,  $250^\circ\text{C}$ ; source heater temperature,  $350^\circ\text{C}$ ; sheath gas flow rate, 45 AU; auxiliary gas flow rate, 10 AU; sweep gas flow rate, 1.0 AU; S-Lens RF level, 55%; source voltage, 2.70 kV (ESI $-$  mode) or 3.50 kV (ESI $+$  mode). The data were acquired in a single analytical batch. Biological samples were randomized in the analytical run, and control quality (QC) samples, consisting of a mix of all biological samples of the same type (that is, plasma and brain samples, respectively), were injected at regular intervals throughout the experiment. Metabolites were identified by extracting the exact mass with a tolerance of 5 ppm. The raw MS isotopic profiles of metabolites were then quantified using TraceFinder (Thermo Fisher Scientific). Isotopologue fractions were obtained after correcting for natural isotopic abundances using IsoCor<sup>60,61</sup> (<https://github.com/MetaSys-LISBP/IsoCor>). Molecular  $^{13}\text{C}$  enrichments were calculated from the sum of the relative abundances of all isotopologues of a metabolite weighted by the number of  $^{13}\text{C}$  atoms in each isotopologue.

### Statistical analysis

For simple comparisons, we used unpaired two-tailed Student's  $t$ -test. For other multiple-value comparisons, we used one-way or two-way ANOVA followed by Tukey's or Bonferroni post hoc tests. All tests used are indicated in each figure legend. Statistical analysis was performed using GraphPad Prism version 8 software. Numbers of biologically independent culture preparations or animals used per experiment are indicated in the figure legends. No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those reported in a previous publication<sup>45</sup>. Data distribution was assumed to be normal, but this was not formally tested. Data collection, assignment and organization of the experimental conditions were randomized. Data collection and analysis were not performed blind to the conditions of the experiments. No animals or data points were excluded from the analyses.

### Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

### Data availability

Source data are provided with this paper.

### References

1. Diemel, G. A. Brain glucose metabolism: integration of energetics with function. *Physiol. Rev.* **99**, 949–1045 (2019).
2. Bonvento, G. & Bolaños, J. P. Astrocyte–neuron metabolic cooperation shapes brain activity. *Cell Metab.* **33**, 1546–1564 (2021).
3. Herrero-Mendez, A. et al. The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C–Cdh1. *Nat. Cell Biol.* **11**, 747–752 (2009).
4. Zhang, Y. et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. *J. Neurosci.* **34**, 11929–11947 (2014).
5. Zheng, X. et al. Metabolic reprogramming during neuronal differentiation from aerobic glycolysis to neuronal oxidative phosphorylation. *eLife* **5**, e13374 (2016).
6. Cruz, E., Bessieres, B., Magistretti, P. & Alberini, C. M. Differential role of neuronal glucose and PFKFB3 in memory formation during development. *Glia* **70**, 2207–2231 (2022).

7. Visintin, R., Prinz, S. & Amon, A. CDC20 and CDH1: a family of substrate-specific activators of APC-dependent proteolysis. *Science* **278**, 460–463 (1997).
8. Almeida, A., Bolaños, J. P. & Moreno, S. Cdh1/Hct1–APC is essential for the survival of postmitotic neurons. *J. Neurosci.* **25**, 8115–8121 (2005).
9. Li, Z. et al. APC–Cdh1 regulates neuronal apoptosis through modulating glycolysis and pentose-phosphate pathway after oxygen–glucose deprivation and reperfusion. *Cell. Mol. Neurobiol.* **39**, 123–135 (2019).
10. Lopez-Fabuel, I. et al. Aberrant upregulation of the glycolytic enzyme PFKFB3 in CLN7 neuronal ceroid lipofuscinosis. *Nat. Commun.* **13**, 536 (2022).
11. Traxler, L. et al. Warburg-like metabolic transformation underlies neuronal degeneration in sporadic Alzheimer’s disease. *Cell Metab.* **34**, 1248–1263 (2022).
12. Garcia-Higuera, I. et al. Genomic stability and tumour suppression by the APC/C cofactor Cdh1. *Nat. Cell Biol.* **10**, 802–811 (2008).
13. Minichiello, L. et al. Essential role for TrkB receptors in hippocampus-mediated learning. *Neuron* **24**, 401–414 (1999).
14. Bobo-Jimenez, V. et al. APC/C(Cdh1)–Rock2 pathway controls dendritic integrity and memory. *Proc. Natl Acad. Sci. USA* **114**, 4513–4518 (2017).
15. Cohen, S. S. Studies on the distribution of the oxidative pathway of glucose-6-phosphate utilization. *Biol. Bull.* **99**, 369 (1950).
16. Hotherhall, J. S., Baquer, N. Z., Greenbaum, A. L. & McLean, P. Alternative pathways of glucose utilization in brain. Changes in the pattern of glucose utilization in brain during development and the effect of phenazine methosulphate on the integration of metabolic routes. *Arch. Biochem. Biophys.* **198**, 478–492 (1979).
17. Ben-Yoseph, O., Boxer, P. A. & Ross, B. D. Assessment of the role of the glutathione and pentose phosphate pathways in the protection of primary cerebrotical cultures from oxidative stress. *J. Neurochem.* **66**, 2329–2337 (1996).
18. Rodriguez-Rodriguez, P., Fernandez, E. & Bolaños, J. P. Underestimation of the pentose-phosphate pathway in intact primary neurons as revealed by metabolic flux analysis. *J. Cereb. Blood Flow Metab.* **33**, 1843–1845 (2013).
19. Gebriel, H. M., Avula, B., Wang, Y. H., Khan, I. A. & Jekabsons, M. B. <sup>13</sup>C metabolic flux analysis in neurons utilizing a model that accounts for hexose phosphate recycling within the pentose phosphate pathway. *Neurochem. Int.* **93**, 26–39 (2016).
20. Vicente-Gutierrez, C. et al. Astrocytic mitochondrial ROS modulate brain metabolism and mouse behaviour. *Nat. Metab.* **1**, 201–211 (2019).
21. Nissanka, N. & Moraes, C. T. Mitochondrial DNA damage and reactive oxygen species in neurodegenerative disease. *FEBS Lett.* **592**, 728–742 (2018).
22. Burger, N. et al. ND3 Cys39 in complex I is exposed during mitochondrial respiration. *Cell Chem. Biol.* **29**, 636–649 (2022).
23. Tatton, W. G. et al. Glyceraldehyde-3-phosphate dehydrogenase in neurodegeneration and apoptosis signaling. *J. Neural Transm. Suppl.* [https://doi.org/10.1007/978-3-7091-6301-6\\_5](https://doi.org/10.1007/978-3-7091-6301-6_5) (2000).
24. Luengo, A. et al. Increased demand for NAD<sup>+</sup> relative to ATP drives aerobic glycolysis. *Mol. Cell* **81**, 691–707 (2021).
25. Perez-Liebana, I. et al. A Ca<sup>2+</sup>-dependent mechanism boosting glycolysis and OXPHOS by activating Aralar–malate–aspartate shuttle, upon neuronal stimulation. *J. Neurosci.* **42**, 3879–3895 (2022).
26. Bittar, P. G., Charnay, Y., Pellerin, L., Bouras, C. & Magistretti, P. J. Selective distribution of lactate dehydrogenase isoenzymes in neurons and astrocytes of human brain. *J. Cereb. Blood Flow Metab.* **16**, 1079–1089 (1996).
27. Verschuere, K. H. G. et al. Structure of ATP citrate lyase and the origin of citrate synthase in the Krebs cycle. *Nature* **568**, 571–575 (2019).
28. Kumar, A. et al. NaCT/SLC13A5 facilitates citrate import and metabolism under nutrient-limited conditions. *Cell Rep.* **36**, 109701 (2021).
29. Ferreira, C. R., Silber, M. H., Chang, T., Murnick, J. G. & Kirmse, B. Cerebral lipid accumulation detected by MRS in a child with carnitine palmitoyltransferase 2 deficiency: a case report and review of the literature on genetic etiologies of lipid peaks on MRS. *JIMD Rep.* **28**, 69–74 (2016).
30. Jung, Y. H. et al. Aberrant interactions of peripheral measures and neurometabolites with lipids in complex regional pain syndrome using magnetic resonance spectroscopy: a pilot study. *Mol. Pain.* **14**, 1744806917751323 (2018).
31. Girard, V. et al. Abnormal accumulation of lipid droplets in neurons induces the conversion of  $\alpha$ -synuclein to proteolytic resistant forms in a *Drosophila* model of Parkinson’s disease. *PLoS Genet.* **17**, e1009921 (2021).
32. Lee, I. H. et al. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. *Proc. Natl Acad. Sci. USA* **105**, 3374–3379 (2008).
33. Boyd, S. et al. Structure-based design of potent and selective inhibitors of the metabolic kinase PFKFB3. *J. Med. Chem.* **58**, 3611–3625 (2015).
34. Kaushik, S. et al. Autophagy in hypothalamic AgRP neurons regulates food intake and energy balance. *Cell Metab.* **14**, 173–183 (2011).
35. Juaristi, I. et al. ARALAR/AGC1 deficiency, a neurodevelopmental disorder with severe impairment of neuronal mitochondrial respiration, does not produce a primary increase in brain lactate. *J. Neurochem.* **142**, 132–139 (2017).
36. McKenna, M. C., Waagepetersen, H. S., Schousboe, A. & Sonnewald, U. Neuronal and astrocytic shuttle mechanisms for cytosolic–mitochondrial transfer of reducing equivalents: current evidence and pharmacological tools. *Biochem. Pharmacol.* **71**, 399–407 (2006).
37. Rodriguez-Rodriguez, P., Fernandez, E., Almeida, A. & Bolaños, J. P. Excitotoxic stimulus stabilizes PFKFB3 causing pentose-phosphate pathway to glycolysis switch and neurodegeneration. *Cell Death Differ.* **19**, 1582–1589 (2012).
38. Diaz-Garcia, C. M. et al. Neuronal stimulation triggers neuronal glycolysis and not lactate uptake. *Cell Metab.* **26**, 361–374 (2017).
39. Wolfe, A. D. et al. Local and dynamic regulation of neuronal glycolysis in vivo. *Proc. Natl Acad. Sci. USA* **121**, e2314699121 (2024).
40. Zala, D. et al. Vesicular glycolysis provides on-board energy for fast axonal transport. *Cell* **152**, 479–491 (2013).
41. Ketschek, A., Sainath, R., Holland, S. & Gallo, G. The axonal glycolytic pathway contributes to sensory axon extension and growth cone dynamics. *J. Neurosci.* **41**, 6637–6651 (2021).
42. Santos, R. et al. Local glycolysis fuels actomyosin contraction during axonal retraction. *J. Cell Biol.* **222**, e202206133 (2023).
43. Wei, Y. et al. Aerobic glycolysis is the predominant means of glucose metabolism in neuronal somata, which protects against oxidative damage. *Nat. Neurosci.* **26**, 2081–2089 (2023).
44. Almeida, A., Moncada, S. & Bolaños, J. P. Nitric oxide switches on glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase pathway. *Nat. Cell Biol.* **6**, 45–51 (2004).
45. Morant-Ferrando, B. et al. Fatty acid oxidation organizes mitochondrial supercomplexes to sustain astrocytic ROS and cognition. *Nat. Metab.* **5**, 1290–1302 (2023).
46. Guzman, M. & Blazquez, C. Is there an astrocyte–neuron ketone body shuttle? *Trends Endocrinol. Metab.* **12**, 169–173 (2001).
47. Di Lucente, J. et al. Ketogenic diet and BHB rescue the fall of long-term potentiation in an Alzheimer’s mouse model and stimulates synaptic plasticity pathway enzymes. *Commun. Biol.* **7**, 195 (2024).
48. Lopez-Fabuel, I. et al. Complex I assembly into supercomplexes determines differential mitochondrial ROS production in neurons and astrocytes. *Proc. Natl Acad. Sci. USA* **113**, 13063–13068 (2016).



49. Vicente-Gutierrez, C. & Bolaños, J. P. An ex vivo approach to assess mitochondrial ROS by flow cytometry in AAV-tagged astrocytes in adult mice. *Bio Protoc.* **10**, e3550 (2020).
50. Chan, K. Y. et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. *Nat. Neurosci.* **20**, 1172–1179 (2017).
51. Yardeni, T., Eckhaus, M., Morris, H. D., Huizing, M. & Hoogstraten-Miller, S. Retro-orbital injections in mice. *Lab Anim.* **40**, 155–160 (2011).
52. Rodriguez, C. et al. Neovascularization and functional recovery after intracerebral hemorrhage is conditioned by the Tp53 Arg72Pro single-nucleotide polymorphism. *Cell Death Differ.* **24**, 144–154 (2017).
53. Bolaños, J. P. & Medina, J. M. Lipogenesis from lactate in fetal rat brain during late gestation. *Pediatr. Res.* **33**, 66–71 (1993).
54. Folch, J., Lees, M. & Sloane-Stanley, G. H. A simple method for the isolation and purification of total lipides from animal tissues. *J. Biol. Chem.* **226**, 497–509 (1957).
55. Ragan, C. I., Wilson, M. T., Darley-Usmar, V. M. & Lowe, P. N. In *Mitochondria: A Practical Approach* (eds Rickwood, D. et al.) 79–112 (IRL Press, 1987).
56. King, T. E. Preparation of succinate cytochrome c reductase and the cytochrome b–c<sub>1</sub> particle, and reconstitution of succinate cytochrome c reductase. *Methods Enzymol.* **10**, 216–225 (1967).
57. Shepherd, J. A. & Garland, P. B. Citrate synthase from rat liver. *Methods Enzymol.* **13**, 11–19 (1969).
58. Van Schaftingen, E., Lederer, B., Bartrons, R. & Hers, H. G. A kinetic study of pyrophosphate: fructose-6-phosphate phosphotransferase from potato tubers. Application to a microassay of fructose 2,6-bisphosphate. *Eur. J. Biochem.* **129**, 191–195 (1982).
59. Provencher, S. W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. *Magn. Reson. Med.* **30**, 672–679 (1993).
60. Millard, P., Letisse, F., Sokol, S. & Portais, J. C. IsoCor: correcting MS data in isotope labeling experiments. *Bioinformatics* **28**, 1294–1296 (2012).
61. Millard, P. et al. IsoCor: isotope correction for high-resolution MS labeling experiments. *Bioinformatics* **35**, 4484–4487 (2019).

## Acknowledgements

We acknowledge the technical assistance of M. Resch, M. Carabias-Carrasco, L. Martin and E. Prieto-Garcia from the University of Salamanca. E. Prieto-García was a recipient of a position by the Fondo Social Europeo, Youth Employment Initiative, Junta de Castilla y León. Staff members (A. Rocher, H. Kulyk, N. Lager-Lachaud, L. Gales, F. Bellvert) of MetaToul (Toulouse, France, <https://metatoul.fr>) are gratefully acknowledged for technical support and access to MS facilities. The projects that gave rise to these results were funded by MICIU/AEI (PID2022-138813OB-I00, PID2019-105699RB-I00/10.13039/501100011033 and FEDER, UE to J.P.B.; SAF2017-90794-REDT to A.A.), la Caixa Foundation (grant agreement LCF/PR/HR23/52430016 to J.P.B.), the Instituto de Salud Carlos III (CB16/10/00282 to J.P.B.; PI21/00727, RD16/0019/0018, PMP22/00084 to A.A.), the Junta de Castilla y León (CSI011P23 and Escalera de Excelencia CLU-2017-03 to J.P.B. and A.A.) and the European

Union's Horizon Europe research and innovation programme under MSCA Doctoral Networks 2021 (101072759, FuEL The bRaiN In healthY aging and age-related diseases (ETERNITY), to J.P.B. and A.A.). MetaToul is part of the national infrastructure MetaboHUB and is funded by the French National Research Agency (ANR) with grant number MetaboHUB-ANR-11-INBS-0010.

## Author contributions

Conceived the idea and designed research: J.P.B. Performed research: D.J.-B., J.A., R.L., M.G.-M., V.B.-J., D.G.-R., I.M.-R., E.F., Y.J., S.K., J.-C.P., D.P., P.R.-C., A.A. Analysed data: J.P.B., A.A., D.J.-B., J.A., R.L., M.G.-M., V.B.-J., D.G.-R., I.M.-R., E.F., Y.J., S.K., J.-C.P., D.P., P.R.-C., A.A. Contributed materials: P.C. Wrote the manuscript: J.P.B. Edited and approved the manuscript: all co-authors.

## Competing interests

The authors declare no competing interests.

## Additional information

**Extended data** is available for this paper at <https://doi.org/10.1038/s42255-024-01049-0>.

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s42255-024-01049-0>.

**Correspondence and requests for materials** should be addressed to Juan P. Bolaños.

**Peer review information** *Nature Metabolism* thanks Beatriz Pardo, Mark Mattson and James Hurley for their contribution to the peer review of this work. Primary Handling Editor: Alfredo Giménez-Cassina, in collaboration with the *Nature Metabolism* team.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024

<sup>1</sup>Institute of Functional Biology and Genomics, Universidad de Salamanca, CSIC, Salamanca, Spain. <sup>2</sup>Institute of Biomedical Research of Salamanca (IBSAL), Hospital Universitario de Salamanca, Universidad de Salamanca, CSIC, Salamanca, Spain. <sup>3</sup>Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable, Madrid, Spain. <sup>4</sup>RESTORE, University of Toulouse, Inserm U1031, CNRS 5070, UPS, EFS, Toulouse, France. <sup>5</sup>MetaboHUB-MetaToul, National Infrastructure of Metabolomics and Fluxomics, Toulouse, France. <sup>6</sup>Toulouse Biotechnology Institute, INSA de Toulouse INSA/CNRS 5504, UMR INSA/INRA 792, Toulouse, France. <sup>7</sup>CIC biomaGUNE, Basque Research and Technology Alliance, Donostia-San Sebastián, Spain. <sup>8</sup>Ikerbasque, Basque Foundation for Science, Bilbao, Spain. <sup>9</sup>Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology and Leuven Cancer Institute (LKI), KU Leuven, VIB Center for Cancer Biology, VIB, Leuven, Belgium. <sup>10</sup>Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.


✉ e-mail: [jbolanos@usal.es](mailto:jbolanos@usal.es)





**Extended Data Fig. 1 | *In vivo* neuron-specific *Pfkfb3* expression activates glycolysis and inhibits PPP causing redox stress.** (a) Immunocytochemical confocal images in neuron-specific *Cdh1* knockout mice (*Camk1 $\alpha$ -Cdh1*<sup>-/-</sup>). NeuN and DAPI identify neurons and nuclei, respectively. Bar=20  $\mu\text{m}$  ( $n = 3$  mice per genotype). (b) Western blot quantifications for Fig. 1b. Data are mean  $\pm$  S.E.M. *P* value is indicated ( $n = 3$  mice per genotype; Unpaired Student's *t*-test, two-sided). (Uncropped western blot replicas are shown as Source Data file). (c) Immunocytochemical confocal images in *Camk1 $\alpha$ -Pfkfb3* mice. Bar=20  $\mu\text{m}$ . ( $n = 3$  mice per genotype). (d) Western blot quantifications for Fig. 1c. Data are mean  $\pm$  S.E.M. *P* value is indicated ( $n = 3$  mice per genotype; Unpaired Student's *t*-test, two-sided). (Uncropped western blot replicas are shown as Source Data file). (e) Voxel localization of  $[^1\text{H}]$ MRS analyzed brain areas (left) and representative  $^1\text{H}$  spectrum (right). Related to Fig. 1d,i. (f) Preliminary experiment for the  $^{13}\text{C}$ -glucose-mass spectrometry (MS) analysis. WT fed or fasted (6 h) mice were injected (i.p.) with a bolus of glucose (2 g/kg), and blood glucose was determined to estimate the time at which glucose levels reached the


steady-state concentration ( $\sim 20$  min). Data are average values from 2 technical replicas in 2 mice. Related to Fig. 1e. (g) *In vivo* F6P and F16BP concentrations analyzed by MS in the mice brain extracts. Data are mean  $\pm$  S.E.M. *P* value is indicated ( $n = 4$  mice per genotype; Unpaired Student's *t*-test, two-sided). Related to Fig. 1e. (h) Western blot against *Pfkfb3* protein and quantification.  $\beta$ -Actin, loading control. Data are mean  $\pm$  S.E.M. *P* value is indicated ( $n = 3$  mice per genotype; Unpaired Student's *t*-test, two-sided). (Uncropped western blot replicas are shown as Source Data file). (i)  $^{14}\text{CO}_2$  production from  $[1-^{14}\text{C}]$ glucose (left) and  $[6-^{14}\text{C}]$ glucose (right) in primary neurons. Data are mean  $\pm$  S.E.M. *P* value is indicated;  $n = 6$  (WT) or 8 (*Pfkfb3*) biologically independent cell culture preparations; Unpaired Student's *t*-test, two-sided). Related to Fig. 1j. (j) Total (left), oxidized (middle) and reduced (right) glutathione concentrations in primary neurons. Data are mean  $\pm$  S.E.M. *P* value is indicated;  $n = 9$  (WT) or 12 (*Pfkfb3*) biologically independent cell culture preparations; Unpaired Student's *t*-test, two-sided). Related to Fig. 1k.



Extended Data Fig. 2 | See next page for caption.

**Extended Data Fig. 2 | Neuron-specific *Pfkfb3* expression impairs mitochondrial bioenergetics via enhanced mitochondrial ROS.** (a) Strategy used to generate the neuron-specific double transgenic *Pfkfb3*-mCat mice (*Camk11a-Pfkfb3-mCat*) and its corresponding control (*Camk11a-mCat*). (b) Adenoviral transduction strategy used to express double transgenic *Pfkfb3*-mCat in brain cortical neurons in primary culture from *Pfkfb3<sup>lox/+</sup>; mCat<sup>lox/+</sup>* mice and its corresponding control (mCat, obtained from *mCat<sup>lox/+</sup>*). Transduction of *Pfkfb3<sup>lox/+</sup>* neurons with adenovirus harboring (or not) Cre, generated *Pfkfb3* or their corresponding WT (*Pfkfb3<sup>lox/+</sup>*) neurons. Created with BioRender.com. (c) IGA-CI and BNGE quantifications for Fig. 2g. Data are mean  $\pm$  S.E.M. *P* value is indicated (n = 3 mice per genotype; One-way ANOVA followed by Tukey). (Uncropped western blot replicas are shown in the Source Data file). (d)  $\Delta\psi_m$

assessment by confocal analysis in primary neurons. Data are mean  $\pm$  S.E.M. *P* value is indicated; n = 8 (WT, *Pfkfb3*-mCat), 7 (*Pfkfb3*) or 6 (mCat) biologically independent cell culture preparations; one-way ANOVA followed by Bonferroni. Bar = 20  $\mu$ m. (e) Volcano plot (left) and heatmap (right) of the metabolomics analysis of the brain of *Camk11a-Pfkfb3* versus the corresponding WT mice. Citrate levels (fold-change, mean  $\pm$  S.E.M.):  $0.81 \pm 0.0253$  (*P* = 0.0345; n = 6 per genotype; Welch's two-sample *t* test). (f)  $\Delta\psi_m$  analysis of hippocampal or MBH neurons freshly isolated from mice of the different genotypes previously transduced with adeno-associated viral particles expressing GFP under the neuron-specific *hSyn* promoter. Data are mean  $\pm$  S.E.M. *P* value is indicated; n = 5 (WT) or 4 (*Camk11a-Pfkfb3*, *Camk11a-mCat*, *Camk11a-Pfkfb3-mCat*) mice; one-way ANOVA followed by Bonferroni. Related to Fig. 2d.




Extended Data Fig. 3 | See next page for caption.



**Extended Data Fig. 3 | Neuron-specific *Pfkfb3* expression causes increased lipogenesis, lipid droplets accumulation and inhibition of sirtuin-mediated autophagy.** (a) Rates of glucose consumption and lactate release. Data are averages; 3 replica of a cell culture preparation per condition. (b) *In vivo* [<sup>1</sup>H] MRS analysis of lipid13A/(pCr+Cr) and lipid13A + 13B/(pCr+Cr) in mice brain. Data are mean ± S.E.M. *P* value is indicated; n = 5 mice per genotype; Unpaired Student's *t*-test, two-sided. (c) Western blot against perilipin 2 (Plin2). Data are mean ± S.E.M. *P* value is indicated; n = 3 biologically independent cell culture preparations; Unpaired Student's *t*-test, two-sided. (Uncropped western blot replicas are shown as Source Data file). (d) Western blot in brain cells. Gfap and Tuj1, loading controls for astrocytes and neurons, respectively. Data are mean ± S.E.M. *P* value is indicated (n = 3 mice per genotype; Unpaired Student's *t*-test, two-sided). (Uncropped western blot replicas are shown in the Source Data file). (e) Shuttles. 2- + 3-phosphoglycerate (2-3PG) was used as a proxy of dihydroxyacetone-phosphate. Data are mean ± S.E.M. *P* value is indicated

(n = 6 mice per genotype; Unpaired Student's *t*-test, two-sided). (<sup>13</sup>C-enriched metabolites are shown in the Source Data file). (f-h) Western blot quantifications for Fig. 3e,f,g. Data are mean ± S.E.M. *P* values are indicated; n = 4 (f), 3 (g), 3 (h) biologically independent cell culture preparations. Unpaired Student's *t*-test, two-sided (f,h), two-way ANOVA followed by Tukey (g). (Uncropped western blot replicas are shown in the Source Data file). (i) Western blot and quantifications. Data are mean ± S.E.M. *P* value is indicated; n = 3 mice per genotype; Unpaired Student's *t*-test, two-sided. (Uncropped western blot replicas are shown as Source Data file). (j) NAD<sup>+</sup> concentrations after NMN treatment for 1 month. Data are mean ± S.E.M. *P* value is indicated; n = 3 (*WT* AAV), 7 (*WT* AAV + NMN), 5 (*CamkIIα-Pfkfb3* AAV) or 6 (*CamkIIα-Pfkfb3* AAV + NMN) mice; two-way ANOVA followed by Bonferroni. (k) Western blot quantifications for Fig. 3i. Data are mean ± S.E.M. *P* value is indicated; n = 3 mice per genotype; two-way ANOVA followed by Tukey. (Uncropped western blot replicas are shown as Source Data file).




Extended Data Fig. 4 | See next page for caption.

**Extended Data Fig. 4 | Neuron-specific *Pfkfb3* expression causes motor and cognitive impairments via mitochondrial ROS. (a)** *In vivo* [<sup>1</sup>H]MRS analysis of NAA + NAAG/(pCr+Cr) in the brain of WT and *Camk11α-Pfkfb3* mice. Data are mean ± S.E.M. *P* value is indicated; n = 5 mice per genotype; Unpaired Student's *t*-test, two-sided. **(b)** Immunocytochemical analysis of hippocampal slices against GFAP and DAPI from WT and *Camk11α-Pfkfb3* mice. Data are mean ± S.E.M. *P* value is indicated; n = 4 mice per genotype; Unpaired Student's *t*-test, two-sided. Bar=20 μm. **(c)** Apoptosis analysis of hippocampal or MBH neurons freshly isolated from mice of the different genotypes previously transduced with adeno-associated viral particles expressing GFP under the neuron-specific *hSyn* promoter. Data are mean ± S.E.M. *P* value is indicated; n = 5 (WT) or 4 (*Camk11α-Pfkfb3*, *Camk11α-mCat*, *Camk11α-Pfkfb3-mCat*) mice; one-way ANOVA followed by Bonferroni. Related to Fig. 2d. **(d)** Immunocytochemical analysis of hippocampal


slices against Tuj1 and DAPI from WT, *Camk11α-Pfkfb3*, *Camk11α-mCat* and *Camk11α-Pfkfb3-mCat* mice. Data are mean ± S.E.M. *P* value is indicated; n = 3 mice per genotype; one-way ANOVA followed by Bonferroni. Bar=20 μm. **(e)** Open field test analysis in mice. Data are mean ± S.E.M. *P* value is indicated; n = 12 (WT), 9 (*Camk11α-Pfkfb3*), 7 (*Camk11α-mCat*, *Camk11α-Pfkfb3-mCat*) mice; one-way ANOVA followed by Bonferroni. Related to Fig. 3. **(f,g)** Rotarod (f) and treadmill (g) tests in mice of the indicated genotypes. Data are mean ± S.E.M. *P* value is indicated; n = 12 (WT), 9 (*Camk11α-Pfkfb3*) or 7 (*Camk11α-mCat*, *Camk11α-Pfkfb3-mCat*) mice; one-way ANOVA followed by Bonferroni. **(h-k)** Open field (h), rotarod (i), treadmill (j) and novel object recognition (k) tests in female mice of the indicated genotypes. Data are mean ± S.E.M. *P* value is indicated; n = 10 (WT) or 9 (*Camk11α-Pfkfb3*) mice; Unpaired Student's *t*-test, two-sided.





**Extended Data Fig. 5 | Motor and cognitive impairments caused by neuron-specific *Pfkfb3* expression is rescued by restoring brain NAD<sup>+</sup> levels. (a,b) Rotarod (a) and Open Field (b) tests in mice of the indicated genotypes.**

Data are mean  $\pm$  S.E.M. *P* value is indicated; *n* = 4 (*WT* AAV), 7 (*WT* AAV + NMN), 5 (*CamkIIα-Pfkfb3* AAV) or 6 (*CamkIIα-Pfkfb3* AAV + NMN) mice; two-way ANOVA followed by Tukey.



**Extended Data Fig. 6 | Neuronal *Pfkfb3* induces a mROS-mediated metabolic-like syndrome that is mimicked by confining *Pfkfb3* expression in mediobasal hypothalamic neurons.** (a) Body weight analysis in mice. Data are mean  $\pm$  S.E.M. *P* value is indicated; for 2.5 months, *n* = 14 (WT), 20 (*Camk1 $\alpha$ -Pfkfb3*), 9 (*Camk1 $\alpha$ -mCat*) or 13 (*Camk1 $\alpha$ -Pfkfb3-mCat*) mice; for 8 months, *n* = 8 (WT), 9 (*Camk1 $\alpha$ -Pfkfb3*), *Camk1 $\alpha$ -mCat*) or 7 (*Camk1 $\alpha$ -Pfkfb3-mCat*) mice; one-way ANOVA followed by Bonferroni. (b) Analysis of the area under the curve for Fig. 4a. Data are mean  $\pm$  S.E.M. *P* value is indicated; *n* = 12 (WT), 14 (*Camk1 $\alpha$ -Pfkfb3*), 9 (*Camk1 $\alpha$ -mCat*) or 12 (*Camk1 $\alpha$ -Pfkfb3-mCat*) mice; one-way ANOVA followed by Tukey. (c) Weight gain in *Cln7 $\Delta$ ex2* and WT mice that daily received the *Pfkfb3* inhibitor AZ67 (1 nmol/day) (or DMSO) intracerebroventricularly for 2.5 months. Data are mean  $\pm$  S.E.M. *P* value is indicated; *n* = 4 mice per genotype; Unpaired Student's *t*-test, two-sided. (d) Weight of the indicated tissues in mice. Data are mean  $\pm$  S.E.M. *P* value is indicated; *n* = 6 (WT, *Camk1 $\alpha$ -Pfkfb3*) or 5 (*Camk1 $\alpha$ -mCat*, *Camk1 $\alpha$ -Pfkfb3-mCat*) mice; one-way ANOVA followed by

Bonferroni. (e) Weight of the indicated tissues in mice. Data are mean  $\pm$  S.E.M. *P* value is indicated; liver, *n* = 9 (WT), 11 (*Camk1 $\alpha$ -Pfkfb3*), 6 (*Camk1 $\alpha$ -mCat*) or 9 (*Camk1 $\alpha$ -Pfkfb3-mCat*) mice; gastrocnemius, *n* = 7 (WT), 11 (*Camk1 $\alpha$ -Pfkfb3*), 6 (*Camk1 $\alpha$ -mCat*) or 10 (*Camk1 $\alpha$ -Pfkfb3-mCat*) mice; one-way ANOVA followed by Tukey. (f) Analysis of the area under the curve of glucose tolerance test of Fig. 4g. Data are mean  $\pm$  S.E.M. *P* value is indicated; *n* = 6 (WT), 4 (*Camk1 $\alpha$ -Pfkfb3*), 5 (*Camk1 $\alpha$ -mCat*) or 4 (*Camk1 $\alpha$ -Pfkfb3-mCat*) mice; one-way ANOVA followed by Tukey. (g) Western blot quantifications for Fig. 4h. Data are mean  $\pm$  S.E.M. *P* value is indicated; *n* = 3 mice per genotype; one-way ANOVA followed by Tukey. (Uncropped western blot replicas are shown in the Source Data file). (h) Open field test analysis in WT and MBH-nPfkfb3 mice. Data are mean  $\pm$  S.E.M. *n* = 7. Unpaired Student's *t*-test, two-sided. (i-l) Data are mean  $\pm$  S.E.M. *P* value is indicated; *n* = 6 (j, m) or 7 (k, l) mice per genotype; Unpaired Student's *t*-test, two-sided. (l, related to Fig. 4m).

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | n/a                                 | Confirmed  |
|-------------------------------------|--|
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> The statistical test(s) used AND whether they are one- or two-sided<br><i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A description of all covariates tested   |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> For null hypothesis testing, the test statistic (e.g. $F$ , $t$ , $r$ ) with confidence intervals, effect sizes, degrees of freedom and $P$ value noted<br><i>Give <math>P</math> values as exact values whenever suitable.</i>                            |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings  |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes  |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated  |

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection CellQuest Pro v5, Tecnai™, QuantaSmart for TriCarb 5.1 (Perkin Elmer), AMI-maze® interface and ANY-maze® 5.33 software, Seahorse Wave Desktop Software 2.6.1.56, BioRad CFX Maestro 1.1, Harmony 4.9, Fluoview FV10-ASW, Vilber® Fusion FX6 Edge, IsoCor v2.2.2

Data analysis Adobe Photoshop 12, ImageJ 1.48V, Paint-A-Gate™ version PRO, GraphPad Prism v8.0, IBM SPSS 23.0, Canvas draw X, Microsoft Excel (Microsoft 365), Fluoview FV10-ASW, Seahorse Wave Desktop Software 2.6.1.56, MetaboAnalyst 5.0.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Source data and western blot replicas for each figure are provided with this paper in the Source Data file. Original uncropped immunoblots that support all the figures and findings of this study are also available.



## Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

Reporting on sex and gender	N/A
Population characteristics	N/A
Recruitment	N/A
Ethics oversight	N/A

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences     Behavioural & social sciences     Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	We estimated the sample sizes for each type of experiment according to the ARRIVE guidelines in order to obtain a minimum power of 0.8 (80%) with the fewest possible animals (Krzywinski & Altman, Power and sample sizes, Nat Methods 2013, 10:1139, doi.org/10.1038/nmeth.2738; Button et al., Power failure: why small sample size undermines the reliability of neuroscience, Nat Rev Neurosci 2013, 14:365, doi.org/10.1038/nrn3475). We optimized the experimental protocols by performing pilot experiments in order to maximize the differences between conditions. In addition, we estimated the sample sizes by the previous experience of the group in in vitro molecular experiments and in vivo experiments and/or on previously published similar experiments. Exact information on the sample numbers being analyzed can be found in Figure legends and in Supplementary Information. The majority of biochemical assays were repeated at least three times in order to derive statistical information such as error bars, p values and significance.
Data exclusions	No data were excluded from analyses.
Replication	In vitro: experiments were done from 3 to 5 times with independent biological samples and the necessary technical replicates for each technique (typically, 4-6 replicas), in order to reproduce the results found. In vivo: the sample size of the behavioral studies was higher than in the in vitro experiments given the variability in the parameters measured in order to confirm a reliable result. This information has been added in the Statistical section of the manuscript. All attempts at replication were successful. In vivo experiments were performed in 3-12 mice (usually 7-12) per condition.
Randomization	For all mouse experiments, animals were chosen based on genotypes. Aged-matched wild-type and mutant littermates were compared to minimize variance in age, genetic background and environment. Then a general method of randomization to assign experimental groups was not performed because all experiments were conducted with appropriate positive and negative controls, therefore it was not applicable. For in vitro studies, randomization is not applicable as cells with different treatments or genetic knockdown cannot be randomized.
Blinding	Blinding was not considered to be necessary in biochemical, blotting and imaging experiments because they were analyzed in exactly the same manner. For in vivo analysis, all experiments were done by experienced researchers blind for the experimental conditions.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

## Materials &amp; experimental systems

n/a	<input type="checkbox"/>	Involved in the study
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Palaeontology and archaeology
<input type="checkbox"/>	<input checked="" type="checkbox"/>	Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Dual use research of concern

## Methods

n/a	<input type="checkbox"/>	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/>	ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/>	Flow cytometry
<input type="checkbox"/>	<input checked="" type="checkbox"/>	MRI-based neuroimaging

## Antibodies

## Antibodies used

## Primary antibodies:

GFAP (clone 2e8, G6171; Sigma ,1/500), B-Tubulin III (T2200; Sigma ,1/500), NeuN (clone A-60, MAB377; Merck, 1/1000), Cyclin B1 (clone D-11, sc-7393; Santa Cruz Biotechnology, 1/500), Rock2 (clone D-11, sc-398519; Santa Cruz Biotechnology, 1/500), Plin2 (ab52356; Abcam, 1/500), TOMM20 (clone 4F3, ab56783; Abcam, 1/1000), VDAC (clone Ab-5, PC548; Merck, 1/1000), NDUFS1 (clone E-20, sc-50132; Santa Cruz Biotechnology 1/500), UQCRC2 (clone 13G12AF12BB11, ab14745; Abcam, 1/1000 ), NDUFA9 (clone 20C11B11B11, ab14713; Abcam, 1/1000), SDHA (clone 2E3GC12FB2AE2, ab14715; Abcam, 1/1000), MTCO1 (clone 1D6E1A8, ab14705; Abcam, 1/1000), ATPbeta (clone 3D5, ab14730; Abcam, 1/1000), LC3B (#2775; Cell Signaling, 1/1000), p62/SQSTM1 (P0067; Sigma, 1/1000), Atg7 (#2631; Cell Signaling, 1/1000), Acetylated-Lysine (#9441; Cell Signaling, 1/1000), Beclin-1 (clone D40C5, #3495; Cell Signaling, 1/1000), PFKFB3 (clone 3F3, H00005209-M08; Novus Biologicals, 1/500), B-Actin (clone AC-15, A5441; Sigma ,1/30000), -ATPR (MS503, MitoSciences)

## Secondary antibodies:

Goat anti-mouse IgG-HRP (170-6516; Bio-Rad, 1/10000), rabbit anti-goat IgG-HRP (sc-2768, Santa Cruz, 1/10000), goat anti-rabbit IgG-HRP (170-6515; Bio-Rad, 1/10000), goat anti-rabbit-Cy2 (111-225-144, Jackson Immunoresearch, 1/500), goat anti-mouse-Cy5 (115-175-003, Jackson Immunoresearch, 1/500).

## Validation

Antibodies used in this study were validated by the manufacturer who provided references on their websites using the catalog number provided and/or proven to work in the following papers (references belong):

-GFAP (G6171; Sigma, 1/500) was already employed in Vinukonda G et al 2012; Tse KH et al 2014; among others.  
 -beta-Tubulin III (ab18207; Abcam 1/500) was already employed in Choi YS et al 2020; Navneet S et al 2019; among others.  
 -NeuN (clone A-60, MAB377; Merck, 1/1000) was already employed in Linden, JR et al 2015; Herculano-Houzel, S et al 2015; Zuckermann, M et al 2015; among others.  
 -Cyclin B1 (clone D-11, sc-7393; Santa Cruz Biotechnology, 1/500) was employed in DiFederico, E., et al. 1999; Kumar, V., et al. 2017; Fu, S., et al. 2018; among others.  
 -Rock2 (clone D-11, sc-398519; Santa Cruz Biotechnology, 1/500) was employed in Park, Y.H., et al. 2016; Sugimoto, W., et al. 2018; Hou, C., et al. 2018; among others.  
 -TOMM20 (ab56783; Abcam, 1/1000) was already employed in Darna M et al. 2009; Yarham JW et al. 2014; Zhang Y et al. 2020; Mu Y et al. 2021; among others.  
 -VDAC (clone Ab-5, PC548; Merck, 1/1000) was already employed in Crompton, M., et al. 1999; Yu, W.H., et al. 1995; McEnry, M.W., et al. 1993; among others.  
 -NDUFS1 (sc-50132; Santa Cruz Biotechnology 1/500) was already employed in Martin MA et al. 2005; Duncan AM et al. 1992; among others.  
 - UQCRC2 (ab14745; Abcam, 1/1000 ) was already employed in Kremer LS et al. 2017; Zhao QY et al 2020; Chen C et al. 2021; among others.  
 -NDUFA9 (ab14713; Abcam, 1/1000) was already employed in Calvo E et al. 2020; González-García P et al. 2020; among others.  
 -SDHA (ab14715; Abcam, 1/1000) was already employed in Benegiamo G et al. 2022; Greggio C et al. 2017; among others.  
 -MTCO1 (ab14705; Abcam, 1/1000) was already employed in Balsa E et al. 2019; Greggio C et al. 2017; among others.  
 -ATPbeta (clone 3D5, ab14730; Abcam, 1/1000) was employed in Pinson MR et al. 2022; Li X et al. 2022; Long M et al. 2022; among others.  
 -LC3B (#2775; Cell Signaling, 1/1000) was employed in Reggiori, F. and Klionsky, D.J. 2002; Codogno, P. and Meijer, A.J. 2005; Ichimura, Y. et al. 2000; among others.  
 -p62/SQSTM1 (P0067; Sigma, 1/1000) was employed in Bjørkøy, G et al. 2005; Ralston, SH et al. 2008; Klionsky, DJ, and Emr, SD. 2000; among others.  
 -Atg7 (#2631; Cell Signaling, 1/1000) was employed in Reggiori, F and Klionsky, DJ. 2002; Suzuki, K et al. 2001; Mizushima, N et al. 1998; among others.  
 -Acetylated-Lysine (#9441; Cell Signaling, 1/1000) was employed in Boyes, J et al. 1998; Choudhary, C et al. 2009; among others.  
 -Beclin-1 (clone D40C5, #3495; Cell Signaling, 1/1000) was employed in Liang, XH et al. 1999; Liang, XH et al. 2001; Yue, Z et al. 2003; among others.  
 -PFKFB3 (clone 3F3, H00005209-M08; Novus Biologicals, 1/500) was employed in Lopez-Fabuel I and Garcia-Macia M. 2022; Burmistrova O et al. 2019; Almeida A, Bolanos JP and Moncada, 2010; among others.  
 - B-Actin (A5441; Sigma 1/30000) was already employed in Melanie Si Yan Tan et al. 2019; Lorraine Springuel et al 2014; among others.  
 - Plin2 (ab52356; Abcam, 1/500) was employed in Becker, L et al. 2010; Rongbo, L et al. 2022; among others.  
 -HSP60 (ab46798; Abcam) was employed in Lopez-Fabuel I et al Nat Commun 2022, among others.  
 -ATPR (MS503, MitoSciences) was employed by Long et al, EMBO J (2022) among others.  
 -Goat anti-mouse IgG-HRP (170-6516; Bio-Rad) was used by Basu S et al. 2014; Hainer SJ et al, 2016; Yamamoto S et al. 2021

-Rabbit anti-goat IgG-HRP (sc-2768, Santa Cruz) was employed by Zheng FQ et al. 2009; Bruschetta G et al. 2018  
 -Goat anti-rabbit IgG-HRP (170-6515; Bio-Rad) was used by Bhat UG et al. 2015; Zhu H et al. 2022  
 -Goat anti-rabbit-Cy2 (111-225-144, Jackson ImmunoResearch) was used in Baumgartner P et al. 2018; Cerina M et al. 2020  
 -Goat anti-mouse-Cy5 (115-175-003, Jackson ImmunoResearch) was used in Mazo C et al. 2022; Yan B et al. 2022

## Animals and other research organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

Laboratory animals	Cdh1(lox/lox) mice (PMID: 18552834), mCat(lox/+) mice (PMID: 32694785), Pfkfb3(lox/+) mice and Cln( $\Delta$ ex2) mice (PMID: 35087090) were used in C57BL6/J background at the age of 2,5 to 8 months To inactivate Cdh1 gene in neurons of the adult brain, Cdh1(lox/lox) mice were mated with mice carrying the gene encoding Cre recombinase under the control of the CamkIIa promoter (The Jackson Laboratory), generating CamkIIa-Cdh1(-/-) mice. Pfkfb3(lox/+) mice were generated by homologous recombination in the Rosa26 locus of embryonic stem cells under a C57BL/6 background, where we introduced the full-length cDNA of Pfkfb3 preceded by a transcriptional STOP cassette flanked by two loxP sites. This loxP-flanked STOP signal was incorporated between the CAG promoter and the Pfkfb3 cDNA. To express Pfkfb3 in neurons in vivo, Pfkfb3(lox/+) mice were mated with CamkIIa-Cre mice to generate CamkIIa-Pfkfb3. mCat(lox/+) mice were mated with Pfkfb3(lox/+) mice, which generated the double transgenic Pfkfb3(lox/+);mCat(lox/+) mice. Then, Pfkfb3(lox/+);mCat(lox/+) mice were mated with CamkIIa-Cre to generate CamkIIa-Pfkfb3-mCat mice.
Wild animals	No wild animals were used in the study
Reporting on sex	Males and females were used for behavioral analysis observing the same phenotype in both sexes without any evidence of sexual dimorphism. From this moment we used only males for the rest of the study to minimize the number of animals as much as possible.
Field-collected samples	No field collected samples were used in the study.
Ethics oversight	Procedures were approved by the Bioethics Committee of the University of Salamanca or CIC bioGUNE (PET and MRS) in accordance with the Spanish legislation (RD53/2013).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Flow Cytometry

### Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

### Methodology

Sample preparation	Primary neurons or adult brain-cell suspensions were used. These cells were treated with the corresponding probes (Mitoxox, DiIc1, Annexin V or 7AAD), following manufacturer instructions, during a determined time. After incubation with the corresponding probe, the cells were centrifuged and the pellets were resuspended in PBS for further analysis.
Instrument	FACScalibur flow cytometer (BD Biosciences), equipped with a 15 mW argon laser
Software	CellQuest™ v5 for adquisition and Paint-A-Gate™ PRO (BD Biosciences) and FlowJo v10 for data quantification.
Cell population abundance	At least 100,000 events were acquired in triplicate and by condition.
Gating strategy	The threshold of the analyzer was adjusted in the corresponding channel of the flow cytometer to exclude most subcellular residues or cellular aggregates in the SSC/FSC plot. The median intensity values were obtained for each sample, and the FMO (unstained cells) subtracted.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

## Magnetic resonance imaging

### Experimental design

Design type	In vivo magnetic resonance spectroscopy was performed for the determination of metabolites in different brain regions.
-------------	--



Design specifications Animals are kept anesthetized during measurements using 1-1.5% isoflurane. The animal's temperature is maintained around 37.0 °C by means of a hot water circuit and its respiration and temperature are monitored during the acquisition of the MRI experiments using the SAIL M1030 system (SA instruments, NY, USA).  
The MRI session begins with the acquisition of a localization scan to continue with the established protocol, which consists of acquiring axial and sagittal anatomical images that allow selecting the final position of the voxel for spectroscopy.

Behavioral performance measures *State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).*

## Acquisition

Imaging type(s) Structural

Field strength All MRI experiments have been performed at 11.7 Tesla in a Bruker Biospec 117/16 with high performance gradients of 9 cm internal diameter. The experiments have been carried out using a volumetric antenna of 82 mm diameter and a surface antenna optimized for mouse brain as receiver.

Sequence & imaging parameters After fine tuning and shimming of the system water signal FWHM values typically in the 15-25 Hz range were achieved. Scanning started with the acquisition of three scout images (one coronal, one transverse and one sagittal) using a 2D-multiplane T2W RARE pulse sequence with Bruker's default parameters. For 1H-MR a water suppressed PRESS sequence was used with the following parameters: Echo time = 17.336 ms (TE1 = TE2 = 8.668 ms); Repetition time = 2500 ms; Naverages = 256; Acquisition size = 2048 points; spectral width = 11 ppm (5498.53 Hz).

Area of acquisition Those images were used to place the spectroscopy voxel of size 1.8 x 1.8 x 1.8 mm<sup>3</sup> located at the right striatum of the mouse brain or 2 x 0.8 x 2 mm<sup>3</sup> located in cortex (at the mid-line of the brain), always with care not to include the ventricles in the voxel (the geometry of the voxel was slightly altered to avoid this event, when necessary).  
The following parameters are used: STEAM sequence, with VAPOR (Variable Pulse Power and Optimized Relaxation delays) water suppression, TE 3.7 ms, TR 4 seconds, mixing time 10 ms, number of averages 512, BW = 11 ppm, 2K complex points, ACQ time= 34m8s0ms.

Diffusion MRI  Used  Not used

## Preprocessing

Preprocessing software 117/16 USR Bruker Biospec system (Bruker Biospin GmbH, Ettlinglen, Germany) interfaced to an advance III console and operating ParaVicion 6.1 under topspin software (Bruker Biospin). MR spectra were fitted and quantified using LC-Model 6.3-1R.

Normalization The concentrations of the metabolites have been estimated using LCMODEL ver 6.3 ([www.lcmode.com](http://www.lcmode.com)) using a simulated base using FID-A (DOI: 10.1002/mrm.26091). Results are presented normalized to Total Creatine (PCr + CR).

Normalization template *Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g. original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.*

Noise and artifact removal At least two 1H-MRS spectra were acquired per scanning session per animal (5 months-old animals). The voxel was repositioned, and shimming adjustments were repeated between acquired spectra, when the spectral resolution of the obtained 1H-spectrum was not good.

Volume censoring *Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.*

## Statistical modeling & inference

Model type and settings *Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first and second levels (e.g. fixed, random or mixed effects; drift or auto-correlation).*

Effect(s) tested We have observed significant differences between WT and CamkIIa-Pfkfb3 mice in the concentration of some metabolites such as lactate, GSH, NAA. We have used a two-tailed-unpaired t-Test to compare both genotypes.

Specify type of analysis:  Whole brain  ROI-based  Both

Statistic type for inference *Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.*  
(See [Eklund et al. 2016](#))

Correction *Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte Carlo).*

## Models & analysis

- n/a | Involved in the study
- Functional and/or effective connectivity
  - Graph analysis
  - Multivariate modeling or predictive analysis

Functional and/or effective connectivity

*Report the measures of dependence used and the model details (e.g. Pearson correlation, partial correlation, mutual information).*

Graph analysis

*Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, etc.).*

Multivariate modeling and predictive analysis

*Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics.*